Description
Pyruvic Peel 30%
Progressive epidermal renewal, regulation of excess sebum, improvement of skin texture and optimisation of Skin Quality within personalised professional protocols.
Pyruvic Peel 30% TherapDerma is a professional chemical peel formulated with 30% Pyruvic Acid, an alpha-keto acid carefully selected to promote progressive epidermal renewal, contribute to the regulation of excess sebum and progressively improve Skin Quality within personalised professional protocols. It has been developed to promote progressive and clinically controlled epidermal renewal, helping to improve skin texture, regulate excess sebum and optimise the overall appearance of the skin within advanced aesthetic medicine protocols.
Pyruvic Acid combines a high capacity for superficial skin renewal with a marked affinity for skin with excessive sebaceous secretion, helping to refine skin texture, improve the appearance of visible pores and promote a more even, balanced and revitalised complexion when applied under professional supervision.
Its use may contribute to optimising SKIN QUALITY, promoting the balance of oily or acne-prone skin, improving the appearance of superficial textural irregularities, enhancing natural radiance and integrating into protocols aimed at the early signs of photoageing, while always respecting the individual’s biological response and the integrity of the skin barrier.
More than an isolated procedure, Pyruvic Peel 30% forms part of the TherapDerma Clinical Ecosystem™, a methodology based on diagnosis, therapeutic planning, treatment personalisation and continuity of care.
What makes Pyruvic Peel 30% different?
Not all chemical peels are designed to achieve the same clinical objective.
Each acid possesses its own physicochemical characteristics that determine its biological behaviour, its affinity for different skin types and its role within personalised professional protocols.
Pyruvic Peel 30% has been developed for professionals wishing to incorporate progressive epidermal renewal strategies aimed at improving skin texture, controlling excess sebum, refining the appearance of pores and optimising overall skin quality through carefully controlled exfoliation.
Its formulation takes advantage of the characteristic renewing and sebum-regulating properties of Pyruvic Acid, promoting progressive exfoliation compatible with programmes designed to improve Skin Quality, contribute to the balance of acne-prone skin and promote a healthier, more even-looking complexion.
Integrated into a sequential therapeutic plan, it allows the development of progressive treatments adapted to the clinical evolution of each patient while respecting the skin’s biological recovery times.
________________________________________
What is Pyruvic Acid?
Pyruvic Acid is an alpha-keto acid (α-keto acid) widely used in professional aesthetic medicine for its exfoliating properties and its ability to promote progressive epidermal renewal, contribute to the regulation of excess sebum and progressively improve skin texture when incorporated into properly planned clinical protocols. Its biological profile facilitates the gradual removal of superficial corneocytes, helping to keep pores cleaner, promote a visually more even complexion and stimulate the physiological processes responsible for skin renewal.
When incorporated into properly planned professional protocols, it may contribute to improving the appearance of acne-prone skin, smoothing superficial textural irregularities, promoting greater visual uniformity of skin tone and supporting programmes aimed at skin rejuvenation and Skin Quality optimisation.
________________________________________
When should Pyruvic Peel 30% be selected?
Pyruvic Peel 30% may be considered when clinical assessment identifies the need to promote progressive epidermal renewal associated with the control of excess sebum, improvement of skin texture and the overall optimisation of skin quality.
It may be incorporated into personalised protocols for patients presenting with:
• oily skin or excess sebum;
• appropriately selected acne-prone skin;
• enlarged pores;
• irregular superficial skin texture;
• superficial post-acne marks;
• early photoageing;
• loss of radiance;
• thickened or dull-looking skin;
• rejuvenation and Skin Quality programmes;
• protocols aimed at progressively improving the overall appearance of the skin.
The final indication must always be established following an individual clinical assessment performed by the professional.
________________________________________
Position within the TherapDerma Clinical Ladder™
At TherapDerma, we understand that the concentration of a peel is a tool intended to adapt treatment to the specific needs of each patient rather than an indicator of therapeutic superiority.
Each acid and each concentration address different clinical objectives, specific skin profiles and distinct levels of action.
Pyruvic Peel 30% occupies a position intended for protocols designed to promote progressive epidermal renewal, improve skin texture, control excess sebum and optimise Skin Quality in appropriately selected patients.
Treatment progression will always depend on the diagnosis, the individual’s biological response, restoration of the skin barrier function and the clinical reassessment performed by the professional.
It may also be integrated sequentially with other TherapDerma solutions whenever therapeutic planning justifies it, always respecting the physiological intervals between procedures.
________________________________________
TherapDerma Philosophy
At TherapDerma, we believe that the best clinical results do not depend solely on the intensity of exfoliation.
They depend on understanding skin biology, establishing an accurate diagnosis and selecting the most appropriate therapeutic strategy for each patient.
Epidermal renewal acquires real value when it forms part of a rigorous clinical plan capable of optimising skin quality, preserving skin barrier function and promoting progressive improvement based on the individual’s biological response.
For this reason, Pyruvic Peel 30% is integrated into the TherapDerma Clinical Ecosystem™, a working model that combines chemical peels, mesotherapy, medical-aesthetic technologies and home care through personalised protocols based on clinical criteria.
________________________________________
TherapDerma Conclusion
Pyruvic Peel 30% is a clinical tool intended for professionals wishing to incorporate progressive epidermal renewal protocols aimed at improving skin texture, regulating excess sebum and optimising SKIN QUALITY.
Its formulation may contribute to progressively improving the appearance of the skin, promoting greater visual uniformity of texture, optimising skin balance and supporting the physiological processes of epidermal renewal when the procedure is performed under professional supervision.
Its true value lies not only in the concentration of Pyruvic Acid, but also in its ability to integrate into structured therapeutic strategies based on diagnosis, clinical planning, periodic reassessment and continuity of care, enabling the development of personalised treatments consistent with skin physiology and the specific needs of each patient.
Clinical Benefits
Progressive epidermal renewal, regulation of excess sebum, improvement of skin texture and optimisation of Skin Quality within personalised professional protocols.
Pyruvic Peel 30% TherapDerma has been developed to promote progressive, clinically controlled epidermal renewal while respecting skin physiology. It is intended for professionals wishing to incorporate personalised protocols aimed at improving skin texture, regulating excess sebum and optimising Skin Quality.
Thanks to the properties of Pyruvic Acid, this peel combines effective exfoliating action with a remarkable ability to promote the balance of oily-prone skin, contributing to the progressive refinement of skin texture, the visible reduction of pores and a more even, radiant and revitalised complexion.
When incorporated into an individualised clinical protocol, its benefits develop progressively while respecting the skin barrier, the physiological mechanisms of skin renewal and the specific biological response of each patient.
________________________________________
✨ Progressive Epidermal Renewal
What does it contribute clinically?
The chemical exfoliation promoted by Pyruvic Peel 30% encourages the gradual removal of superficial corneocytes, facilitating the reorganisation of the stratum corneum and supporting the physiological processes of epidermal renewal.
This mechanism contributes to optimising the superficial quality of the skin, provided that the procedure forms part of an appropriate clinical treatment plan.
Clinical benefits
✔ Supports progressive epidermal renewal.
✔ Contributes to improving superficial skin texture.
✔ Promotes a more even complexion.
✔ Respects the physiological mechanisms of skin renewal.
________________________________________
💧 Regulation of Excess Sebum
What does it contribute clinically?
Pyruvic Acid has a strong affinity for skin with excessive sebaceous secretion, promoting the progressive balance of the skin surface and helping to maintain a less shiny and more even appearance.
Its use may be incorporated into professional protocols designed to optimise the balance of oily skin without compromising the skin barrier when applied under professional supervision.
Clinical benefits
✔ Helps regulate excess sebum.
✔ Contributes to a more balanced-looking complexion.
✔ Promotes a reduction in the appearance of shine.
✔ Optimises the skin’s surface balance.
________________________________________
🌿 Refinement of Pores and Skin Texture
What does it contribute clinically?
The progressive renewal of the superficial layers of the epidermis promotes the reorganisation of the skin microrelief, helping to improve the appearance of visible pores while providing a progressively smoother and more pleasant skin texture.
Clinical benefits
✔ Contributes to the visible reduction of pores.
✔ Promotes a more even skin texture.
✔ Helps smooth superficial textural irregularities.
✔ Optimises the skin’s visual quality.
________________________________________
🌟 Improvement of Acne-Prone Skin
What does it contribute clinically?
Pyruvic Peel 30% may be incorporated into professional protocols intended for appropriately selected acne-prone skin, promoting controlled superficial renewal and helping to progressively improve the overall appearance of the skin.
Its use contributes to the development of therapeutic strategies aimed at optimising Skin Quality in this type of patient.
Clinical benefits
✔ Promotes the balance of acne-prone skin.
✔ Contributes to improving the appearance of imperfections.
✔ Helps optimise superficial skin texture.
✔ Promotes a visually more even complexion.
________________________________________
🎯 Improvement of Skin Radiance and Tone
What does it contribute clinically?
The gradual renewal of the superficial skin layers promotes a more even reflection of light across the skin, providing a progressively brighter, more even and revitalised appearance.
Clinical improvement continues as treatment sessions progress and the skin completes its physiological renewal processes.
Clinical benefits
✔ Promotes greater radiance.
✔ Contributes to a more even appearance.
✔ Helps revitalise the appearance of the skin.
✔ Improves the visual perception of skin quality.
________________________________________
🌸 Support for Skin Rejuvenation
What does it contribute clinically?
The renewing action of Pyruvic Acid may contribute to progressively improving the appearance of the early signs of photoageing when incorporated into properly planned clinical protocols.
Its use promotes skin that appears smoother, more even and more youthful.
Clinical benefits
✔ Promotes a more rejuvenated appearance.
✔ Contributes to skin that appears firmer.
✔ Helps improve superficial skin texture.
✔ Progressively optimises Skin Quality.
________________________________________
🧬 Support for Skin Quality
What does it contribute clinically?
Several studies suggest that Pyruvic Acid may support the physiological processes associated with epidermal renewal and contribute to the progressive improvement of overall skin quality when incorporated into properly planned protocols.
Its integration into personalised therapeutic strategies allows the development of programmes aimed at optimising Skin Quality while respecting skin physiology.
Clinical benefits
✔ Promotes overall skin quality.
✔ Contributes to improving skin texture.
✔ Helps optimise surface balance.
✔ Integrates into professional Skin Quality protocols.
________________________________________
📈 Progressive Clinical Improvement
The benefits associated with Pyruvic Peel 30% form part of a progressive biological process and do not depend on a single treatment session.
Clinical response develops progressively as treatment sessions advance, respecting the physiological timing of epidermal renewal, skin barrier function and the individual’s biological adaptation.
Accurate diagnosis, appropriate patient selection and personalised therapeutic planning make it possible to develop protocols consistent with the established clinical objectives.
________________________________________
CLINICAL SUMMARY
Main benefits of Pyruvic Peel 30%
✔ Progressive epidermal renewal.
✔ Regulation of excess sebum.
✔ Refinement of pores and skin texture.
✔ Improvement of acne-prone skin.
✔ Greater radiance and visual uniformity.
✔ Support for skin rejuvenation.
✔ Optimisation of Skin Quality.
✔ Progressive clinical improvement.
________________________________________
THERAPDERMA CLINICAL CONCLUSION
The main clinical value of Pyruvic Peel 30% lies in combining progressive epidermal renewal with the regulation of excess sebum, refinement of skin texture and the gradual improvement of Skin Quality.
Integrated within the TherapDerma Clinical Ecosystem™, it may form part of therapeutic strategies based on diagnosis, clinical planning and periodic reassessment, contributing to the development of personalised, progressive treatments that respect skin physiology and are aimed at achieving natural and clinically predictable results.
Why Choose Pyruvic Peel 30%?
A professional option for epidermal renewal protocols, excess sebum regulation, improvement of skin texture and overall optimisation of Skin Quality.
In professional aesthetic medicine, the choice of a chemical peel should not be based solely on the acid concentration, but on selecting the most appropriate active ingredient for the biological needs of each skin type.
Pyruvic Peel 30% has been developed for professionals who wish to incorporate protocols aimed at promoting progressive epidermal renewal, regulating excess sebum, improving skin texture, refining the appearance of pores and optimising Skin Quality within personalised aesthetic medicine programmes.
Its formulation takes advantage of the renewing and sebum-regulating properties of Pyruvic Acid, promoting the physiological reorganisation of the stratum corneum while contributing to improved skin balance, greater visual uniformity and an enhanced overall appearance.
Rather than simply representing a specific concentration, Pyruvic Peel 30% is a clinical tool intended for patients who require progressive skin renewal, excess sebum control, improved skin texture and optimisation of skin quality through protocols that respect skin physiology.
________________________________________
WHEN CAN IT BE AN APPROPRIATE OPTION?
Pyruvic Peel 30% may be considered when the professional identifies the need to promote progressive epidermal renewal combined with the regulation of excess sebum and improvement of skin texture.
It may be incorporated into personalised protocols intended for:
✔ oily skin or excess sebum;
✔ appropriately selected acne-prone skin;
✔ enlarged pores;
✔ irregular superficial skin texture;
✔ superficial skin imperfections;
✔ superficial post-acne marks;
✔ early photoageing;
✔ loss of radiance;
✔ Skin Quality programmes;
✔ skin rejuvenation protocols;
✔ periodic maintenance of skin quality.
The choice should always be made following an individual clinical assessment that considers the patient’s medical history, skin barrier status, skin sensitivity, previous treatments and therapeutic objectives.
________________________________________
FOR WHICH TYPE OF PROFESSIONAL HAS IT BEEN DESIGNED?
Pyruvic Peel 30% is intended for professionals who understand that skin renewal and the treatment of oily skin require rigorous clinical evaluation, appropriate patient selection and individualised therapeutic planning.
It is particularly useful in clinics wishing to develop personalised protocols aimed at improving skin texture, controlling excess sebum, refining pores and optimising SKIN QUALITY.
Its use requires accurate interpretation of the skin response, assessment of clinical progression and adaptation of treatment frequency and sequence according to each patient’s biological characteristics.
Its versatility allows the design of therapeutic strategies adapted to different ages, phototypes and clinical objectives, while always respecting skin physiology.
________________________________________
THERAPDERMA CLINICAL LADDER™
Each peel addresses a different clinical need.
The TherapDerma Clinical Ladder™ does not represent a mandatory progression between peels.
Each solution should be selected according to:
✔ professional diagnosis;
✔ clinical objective;
✔ physiological skin condition;
✔ integrity of the skin barrier;
✔ therapeutic strategy;
✔ expected tolerance;
✔ clinical experience;
✔ treatment response observed during therapy.
________________________________________
Pyruvic Peel 30%
May be considered for:
✔ oily or seborrhoeic skin;
✔ excess sebum;
✔ acne-prone skin;
✔ enlarged pores;
✔ irregular skin texture;
✔ superficial post-acne marks;
✔ early photoageing;
✔ loss of radiance;
✔ Skin Quality protocols;
✔ skin rejuvenation programmes;
✔ periodic maintenance.
Each protocol should always be adapted according to the professional diagnosis and the individual’s biological response.
________________________________________
QUICK SELECTION GUIDE
Clinical Objective Option That May Be Considered
Excess sebum Pyruvic Peel 30%
Acne-prone skin Pyruvic Peel 30%
Enlarged pores Pyruvic Peel 30%
Irregular skin texture Pyruvic Peel 30%
Superficial post-acne marks Pyruvic Peel 30%
Early photoageing Pyruvic Peel 30%
Skin rejuvenation Pyruvic Peel 30%
Improvement of Skin Quality Pyruvic Peel 30%
Skin Quality programmes Pyruvic Peel 30%
Maintenance protocols Pyruvic Peel 30%
This guide provides general guidance and does not replace an individual clinical assessment.
________________________________________
WHY INTEGRATE IT INTO A PROGRESSIVE PROGRAMME?
Improving skin quality does not depend on a single treatment session.
It should be planned while respecting the physiological mechanisms of epidermal renewal, skin barrier recovery and individual biological adaptation.
Within this approach, Pyruvic Peel 30% may be integrated into progressive programmes designed to control excess sebum, improve skin texture, promote a more even appearance and optimise Skin Quality.
Its use allows the professional to assess the patient’s individual response, reassess clinical progress and adapt subsequent treatment sessions according to the results obtained.
When indicated, it may also be combined sequentially with mesotherapy, PDRN, biostimulation, LED therapy, radiofrequency or other medical-aesthetic technologies.
The integration of these procedures should always respect the physiological skin recovery intervals.
________________________________________
THERAPDERMA CLINICAL CONCLUSION
Pyruvic Peel 30% is a clinical tool intended for professionals wishing to incorporate progressive epidermal renewal protocols aimed at regulating excess sebum, improving skin texture and optimising Skin Quality.
Its ability to promote the physiological reorganisation of the epidermis, contribute to the balance of oily skin and progressively improve the appearance of pores and skin texture allows it to be integrated into therapeutic strategies intended for patients seeking natural, progressive results that respect skin biology.
Within the TherapDerma Clinical Ladder™, it occupies a specific position for protocols focused on skin renewal, oiliness control, progressive rejuvenation and optimisation of overall skin quality.
As part of the TherapDerma Clinical Ecosystem™, it may be incorporated into structured programmes based on diagnosis, therapeutic planning and clinical reassessment, providing a scientific, personalised approach consistent with skin physiology.
Areas of Application
One peel. Different clinical applications depending on the anatomical area, diagnosis and individual biological response.
Pyruvic Peel 30% TherapDerma may be integrated into different professional protocols for progressive epidermal renewal, regulation of excess sebum and optimisation of Skin Quality, adapted to different anatomical areas according to the diagnosis, the functional characteristics of the skin and the established clinical objectives.
Thanks to the renewing and sebum-regulating properties of Pyruvic Acid, it allows the development of clinically controlled procedures designed to improve superficial skin texture, promote a more even complexion, optimise the appearance of pores and contribute to the balance of oily-prone skin.
Although the face is one of its main areas of application, Pyruvic Peel 30% may also be incorporated into protocols intended for other anatomical regions when the clinical assessment confirms adequate skin barrier function and sufficient skin recovery capacity.
Each area presents differences in epidermal thickness, sebaceous density, photoexposure, sensitivity and biological response. For this reason, the application technique, product quantity, treatment area, exposure time and treatment frequency should be carefully individualised.
________________________________________
FACE
One of the main areas of application
The face is one of the anatomical regions where Pyruvic Peel 30% may be incorporated most frequently into professional protocols aimed at improving skin texture, controlling excess sebum and progressively optimising Skin Quality.
Increased sebaceous production, enlarged pores, irregular skin texture, superficial imperfections and the early signs of photoageing may progressively affect the appearance of the skin.
When professionally indicated, the procedure may contribute to improving:
✔ skin texture;
✔ the appearance of pores;
✔ the balance of excess sebum;
✔ the visual uniformity of the skin;
✔ the early signs of photoageing;
✔ SKIN QUALITY.
The intensity of the procedure should be adapted to the different facial regions, paying particular attention to thinner and more sensitive areas.
________________________________________
NECK
Aesthetic continuity within carefully selected protocols
The neck presents anatomical and functional characteristics that differ from those of the face, including lower sebaceous density, more delicate skin and a greater predisposition to photoageing.
Pyruvic Peel 30% may be considered in this region when professional assessment confirms adequate skin barrier function and the need to promote progressive epidermal renewal.
When indicated, it may be incorporated into protocols designed to improve superficial skin texture, promote a more even appearance and maintain aesthetic continuity between the face and the neck.
The amount of product, exposure time and treatment frequency should be carefully adjusted according to the observed clinical response.
________________________________________
DÉCOLLETAGE
Progressive renewal of a photoexposed area
The décolletage is constantly exposed to ultraviolet radiation and may present irregular texture, loss of radiance, superficial tone irregularities and the early signs of photoageing.
In appropriately selected patients, Pyruvic Peel 30% may form part of protocols designed to promote superficial renewal and progressively improve texture, visual tone uniformity and the Skin Quality of this area.
Due to the particular sensitivity of the décolletage, the treatment area, product quantity and treatment frequency should be carefully individualised.
________________________________________
BACK OF THE HANDS
Progressive improvement of superficial appearance
The back of the hands is one of the anatomical regions with the greatest cumulative exposure to ultraviolet radiation and environmental factors, and may present irregular texture, loss of radiance and visible signs of skin ageing.
When professionally indicated and skin barrier function is adequate, Pyruvic Peel 30% may be incorporated into protocols aimed at progressively improving skin texture and optimising skin quality.
Application should always respect the anatomical characteristics of the area, individual sensitivity and skin recovery capacity.
________________________________________
BACK
Body application within carefully selected protocols
The back is one of the main body areas for protocols intended for acne-prone skin, excess sebum, irregular texture and residual superficial marks.
When considered appropriate following clinical assessment, Pyruvic Peel 30% may be incorporated into body protocols designed to promote progressive epidermal renewal and improve skin quality.
It may contribute to:
✔ progressively improving skin texture;
✔ promoting a more even complexion;
✔ optimising sebaceous balance;
✔ improving the appearance of superficial imperfections;
✔ optimising SKIN QUALITY.
The treatment area, total amount of product and treatment frequency should be strictly adapted according to the observed clinical response.
________________________________________
CHEST
Localised skin renewal protocols
Certain areas of the chest may present superficial textural irregularities, excess sebum, tone irregularities or loss of skin uniformity.
When skin barrier function, skin integrity and professional diagnosis allow, Pyruvic Peel 30% may be incorporated into localised protocols designed to progressively improve skin quality.
Application should always be limited to carefully selected areas, avoiding regions with active inflammatory lesions, irritation or impaired skin integrity.
Tolerance, treatment area and recovery capacity should be evaluated before each procedure.
________________________________________
CLINICAL GUIDANCE ACCORDING TO THE TREATMENT AREA
Anatomical Area Main Clinical Objective Clinical Considerations
Face Skin renewal, excess sebum control, improvement of skin texture and Skin Quality. Adapt treatment intensity according to the different facial regions and individual sensitivity.
Neck Maintain aesthetic continuity and promote progressive renewal. Apply with particular caution due to the thinner skin and greater sensitivity of the area.
Décolletage Progressively improve texture, radiance and visual tone uniformity. Carefully individualise the treatment area, product quantity and treatment frequency.
Back of the Hands Progressively improve skin texture and optimise skin quality. Always respect skin recovery capacity and the individual’s biological response.
Back Promote epidermal renewal, improve acne-prone skin and optimise Skin Quality. Adapt product quantity and treatment frequency according to the treatment area and clinical progression.
Chest Progressively improve skin quality in localised areas. Avoid areas with active inflammatory lesions or impaired skin integrity.
________________________________________
MULTI-AREA PROTOCOLS
In selected patients, Pyruvic Peel 30% may be incorporated into therapeutic programmes involving the sequential treatment of different anatomical areas.
The selection of treatment areas should not be based solely on general aesthetic criteria, but on an individual clinical assessment that considers the physiological condition of each area, skin barrier integrity, skin recovery capacity and the established therapeutic objectives.
Treating different areas in separate phases provides greater clinical control and allows more precise adaptation of the protocol to the patient’s individual progression.
When indicated, the therapeutic plan may combine different anatomical areas while always respecting the physiological intervals between procedures, the observed biological response and individual clinical tolerance.
Treatment personalisation is one of the fundamental principles of the TherapDerma Clinical Ecosystem™, promoting progressive, safe therapeutic strategies that are consistent with skin physiology.
________________________________________
CLINICAL CONSIDERATIONS
Pyruvic Peel 30% should always be applied following an individual clinical assessment.
Before each procedure, the professional should evaluate the condition of the skin barrier, skin sensitivity, relevant medical history, previous treatments and the skin’s recovery capacity.
The application technique, product quantity, exposure time and treatment frequency should be adapted to the specific characteristics of each anatomical area and the observed clinical progression.
The individual’s biological response is the main criterion for planning treatment continuation and establishing the most appropriate therapeutic progression.
As with any aesthetic medicine procedure, clinical diagnosis and professional judgement take precedence over any standardised protocol.
________________________________________
QUICK SUMMARY
Pyruvic Peel 30% may be incorporated into professional protocols intended for:
✔ face;
✔ neck;
✔ décolletage;
✔ back of the hands;
✔ back;
✔ chest.
Main objectives:
✔ progressive epidermal renewal;
✔ regulation of excess sebum;
✔ improvement of skin texture;
✔ refinement of the appearance of pores;
✔ optimisation of Skin Quality;
✔ progressive improvement of overall skin quality.
Each procedure should always be adapted according to the clinical diagnosis, the anatomical characteristics of the treatment area and the patient’s individual biological response.
________________________________________
THERAPDERMA CONCLUSION
Pyruvic Peel 30% is a versatile clinical tool for professionals wishing to develop personalised protocols aimed at progressively renewing the skin, regulating excess sebum, improving skin texture and optimising Skin Quality.
Its application should be carefully adapted to the specific characteristics of each anatomical area, while respecting skin barrier function, skin sensitivity and the individual’s biological response.
Integrated into the TherapDerma Clinical Ecosystem™, it allows the design of personalised therapeutic strategies for different anatomical areas, providing a progressive, safe clinical approach that is consistent with skin physiology.
How Does It Work?
Understanding the biological process makes it possible to plan more precise treatment protocols.
Although the application of Pyruvic Peel 30% TherapDerma is carried out over a limited period, the biological response associated with the procedure continues to evolve over the following days.
Each treatment session promotes progressive epidermal renewal, contributing to the reorganisation of the stratum corneum, optimising skin balance, promoting the regulation of excess sebum and progressively improving Skin Quality.
Understanding the different stages of this process allows the professional to correctly interpret clinical progression, adjust treatment frequency and establish realistic expectations for each patient.
Thanks to the renewing and sebum-regulating properties of Pyruvic Acid, this peel promotes progressive exfoliation compatible with protocols designed to improve skin texture, optimise the appearance of pores and respect skin physiology and the integrity of the skin barrier.
________________________________________
EVERYTHING BEGINS AT THE SURFACE OF THE SKIN
The peel first comes into contact with the stratum corneum, the outermost layer of the epidermis.
Over time, the accumulation of corneocytes, excess sebaceous secretion, photoexposure and the reduction of physiological renewal may alter skin texture, promote pore obstruction and progressively modify the appearance of the skin.
The application of Pyruvic Peel 30% promotes progressive chemical exfoliation, helping to reduce cohesion between corneocytes and facilitating their gradual removal.
This process should always be carried out within a professional treatment plan that respects the integrity of the skin barrier, individual tolerance and the skin’s recovery capacity.
________________________________________
STEP 1
Progressive Chemical Exfoliation
Pyruvic Acid acts primarily on the most superficial layers of the stratum corneum, promoting a progressive reduction in cohesion between corneocytes.
As a result, superficial peeling of variable intensity may occur, facilitating the gradual removal of accumulated corneocytes, helping to keep pores cleaner and preparing the skin for its physiological renewal process.
The intensity of the response does not depend solely on the concentration.
It is also influenced by:
✔ the formulation;
✔ the amount applied;
✔ the exposure time;
✔ the professional technique;
✔ the thickness of the stratum corneum;
✔ the functional condition of the skin;
✔ individual sensitivity;
✔ previous treatments.
________________________________________
STEP 2
Physiological Renewal of the Epidermis
Once exfoliation has begun, the epidermis continues its natural renewal process.
The progressive removal of superficial cells promotes a more uniform reorganisation of the stratum corneum and contributes to restoring a smoother skin surface.
This process may be particularly beneficial within personalised protocols intended for:
✔ oily skin;
✔ acne-prone skin;
✔ enlarged pores;
✔ irregular skin texture;
✔ early photoageing;
✔ superficial imperfections.
Clinical progression should always be assessed individually, avoiding the interpretation of more intense peeling as synonymous with a better clinical response.
________________________________________
STEP 3
Regulation of Skin Balance
As epidermal renewal progresses, Pyruvic Acid contributes to restoring the balance of skin with excessive sebaceous secretion and helps progressively optimise the overall appearance of the skin surface.
This process promotes a visually more even complexion, with a more refined texture and a healthier appearance.
Results will always depend on the diagnosis, the biological characteristics of the skin and appropriate therapeutic planning.
________________________________________
STEP 4
Progressive Improvement of Skin Quality
As the epidermis completes its renewal process, the skin surface may become more uniformly organised.
Within an appropriately indicated protocol, the following may progressively be observed:
✔ a more even skin texture;
✔ a more refined appearance of pores;
✔ a visually more balanced complexion;
✔ increased radiance;
✔ a more even skin tone;
✔ progressive improvement of Skin Quality.
These changes develop gradually and should always be assessed while respecting the physiological recovery intervals and the integrity of the skin barrier.
________________________________________
STEP 5
Progressive Clinical Evolution and Professional Reassessment
The response obtained after each treatment session forms part of a biological process that requires time, observation and reassessment.
Clinical progression should not depend on automatically increasing either the exposure time or the frequency of treatment sessions.
When the protocol respects the skin’s physiological recovery and the appropriate intervals between procedures, clinical progression can be maintained in a gradual manner consistent with the established therapeutic objectives.
Each new treatment session should be determined according to:
✔ the observed clinical response;
✔ recovery of skin barrier function;
✔ individual tolerance;
✔ progression of skin texture;
✔ balance of excess sebum;
✔ appearance of pores;
✔ compliance with home care;
✔ previously established therapeutic objectives.
Continuation of the protocol should never be considered automatic.
Each new application should be justified through professional reassessment.
________________________________________
WHY IS IT IMPORTANT TO MAINTAIN A PROGRESSIVE APPROACH?
Improving skin quality does not depend on aggressive procedures.
The objective is to stimulate the physiological mechanisms of renewal while respecting the skin barrier and the skin’s natural recovery capacity.
The biological behaviour of Pyruvic Acid makes it possible to develop progressive protocols aimed at optimising Skin Quality, improving skin texture and promoting skin balance without compromising skin physiology.
The intensity of the procedure, exposure time, treatment frequency and programme duration should always be adapted according to the observed clinical response.
________________________________________
A DIFFERENT RESPONSE IN EVERY PATIENT
Each patient presents unique biological characteristics that influence the response to treatment.
Factors such as phototype, stratum corneum thickness, sebaceous secretion levels, skin barrier integrity, previous treatments, age and home care may influence clinical progression.
For this reason, therapeutic planning should always be individualised and adapted according to the response observed after each treatment session.
Personalisation is one of the fundamental principles of the TherapDerma Clinical Ecosystem™.
________________________________________
SEQUENCE OF THE BIOLOGICAL PROCESS
Professional application
↓
Progressive chemical exfoliation
↓
Reduction in cohesion between corneocytes
↓
Physiological renewal of the epidermis
↓
Reorganisation of the stratum corneum
↓
Improvement of skin texture
↓
Progressive regulation of excess sebum
↓
Progressive optimisation of Skin Quality
________________________________________
KEY PRINCIPLES OF ACTION
✔ progressive chemical exfoliation;
✔ physiological renewal of the epidermis;
✔ regulation of excess sebum;
✔ improvement of skin texture;
✔ progressive recovery of natural radiance;
✔ progressive optimisation of Skin Quality;
✔ respect for the skin barrier;
✔ individualised clinical progression.
________________________________________
THERAPDERMA CONCLUSION
Understanding how Pyruvic Peel 30% works enables the professional to make more precise clinical decisions and adapt each protocol according to the individual’s biological response.
Its mechanism of action combines progressive exfoliation with the reorganisation of the stratum corneum, promoting the physiological renewal of the epidermis, regulation of excess sebum and the gradual improvement of skin texture and Skin Quality.
Integrated into the TherapDerma Clinical Ecosystem™, it may be combined with mesotherapy, biostimulation, PDRN, LED therapy or other medical-aesthetic technologies whenever therapeutic planning indicates.
More than simply understanding how a chemical peel works, understanding this biological process makes it possible to plan progressive, safe treatments that are consistent with skin physiology, optimising Skin Quality through personalised, clinically based treatment protocols.
Mechanism of Action
The science behind the biological response of Pyruvic Acid
The mechanism of action of Pyruvic Peel 30% TherapDerma is based on the controlled interaction between Pyruvic Acid, the formulation, the preparation’s pH and the individual biological characteristics of the skin.
From a scientific perspective, the objective of the procedure is to promote progressive epidermal renewal, contributing to the reorganisation of the stratum corneum, the regulation of excess sebum, the optimisation of Skin Quality and the preservation of the functional integrity of the skin barrier.
The clinical response will always depend on the diagnosis, the functional condition of the epidermis, the patient’s biological characteristics and the correct application of the professional treatment protocol.
________________________________________
ACTION ON THE STRATUM CORNEUM
The stratum corneum constitutes the skin’s first line of defence against the external environment and represents the primary site of action of Pyruvic Peel 30%.
This structure is composed of corneocytes embedded within an organised lipid matrix that maintains superficial cohesion, regulates transepidermal water loss and actively participates in skin barrier function.
The accumulation of corneocytes, excess sebaceous secretion, photoexposure and physiological alterations in epidermal renewal may progressively modify the organisation of this layer, leading to irregular skin texture, more visible pores and reduced skin uniformity.
When clinically indicated, Pyruvic Peel 30% acts on this structure by promoting the progressive reorganisation of the skin microrelief through the characteristic biochemical mechanisms of Pyruvic Acid.
________________________________________
MODULATION OF CORNEOCYTE COHESION
Superficial corneocytes remain attached through specialised protein structures known as corneodesmosomes.
Pyruvic Acid promotes a progressive reduction in cohesion between these cellular junctions, facilitating the physiological desquamation of corneocytes that have completed their biological life cycle.
This mechanism reproduces a natural process of skin renewal, promoting a more uniform reorganisation of the stratum corneum without altering normal physiological processes when applied under professional supervision.
As a result of this physiological process, the skin surface may progressively present a more homogeneous texture, a more refined appearance of pores and improved visual skin quality.
The intensity of this response will always depend on the individual characteristics of the skin and the selected treatment protocol.
________________________________________
EPIDERMAL RENEWAL AND REGULATION OF EXCESS SEBUM
Epidermal renewal is a continuous physiological process through which keratinocytes migrate from the deeper layers of the epidermis until they become functional corneocytes.
The correct organisation of this cycle is essential for maintaining a uniform skin surface, an effective skin barrier and physiological skin balance.
When this process becomes less efficient, corneocytes may accumulate, follicular obstruction may occur and superficial skin texture may progressively deteriorate.
By promoting progressive chemical exfoliation, Pyruvic Peel 30% contributes to a more organised renewal process, helping to improve the balance of excess sebum, optimise skin texture and promote a more even complexion.
________________________________________
BALANCE BETWEEN RENEWAL AND RESPECT FOR THE SKIN BARRIER
One of the distinguishing characteristics of Pyruvic Acid is its ability to promote progressive epidermal renewal while respecting skin physiology when the procedure is performed under professional supervision.
This balance makes it possible to develop renewal protocols compatible with strategies aimed at optimising Skin Quality, improving skin texture and promoting progressive clinical improvement without compromising skin barrier function.
________________________________________
RELATIONSHIP BETWEEN CONCENTRATION, pH AND SKIN RESPONSE
The nominal concentration represents only one of the many factors that influence the clinical behaviour of a chemical peel.
The biological response is also determined by the interaction between different variables:
✔ the pH of the formulation;
✔ the fraction of acid available in its non-ionised form;
✔ the vehicle used;
✔ the actual contact time with the skin;
✔ the application technique;
✔ prior preparation of the skin surface;
✔ the hydration level of the stratum corneum;
✔ the integrity of the skin barrier;
✔ the patient’s individual sensitivity.
For this reason, two formulations with the same nominal concentration may produce different clinical responses.
Professional assessment should always consider all of these variables before determining the intensity of the procedure.
________________________________________
INTEGRATION INTO THERAPEUTIC PROTOCOLS
The clinical versatility of Pyruvic Peel 30% allows it to be incorporated into sequential therapeutic strategies whenever indicated by the clinical diagnosis.
Treatment planning should always respect the physiological epidermal recovery period before introducing any complementary procedure.
Once skin barrier function has been restored, the professional may consider integrating it into combined Skin Quality, biostimulation, PDRN, regenerative mesotherapy or medical-aesthetic technology protocols, selecting each intervention according to the patient’s clinical needs.
The combination of procedures should never follow a predetermined sequence, but rather an individualised treatment plan based on the observed clinical progression.
________________________________________
SCIENCE AT A GLANCE™
Parameter Pyruvic Peel 30%
Active ingredient Pyruvic Acid
Chemical family Alpha-keto acid (α-keto acid)
Primary site of action Stratum corneum
Predominant mechanism Progressive reduction in cohesion between corneocytes
Associated physiological process Epidermal renewal and reorganisation of the stratum corneum
Expected physiological outcome Regulation of excess sebum, improvement of skin texture and optimisation of Skin Quality
Determining variables pH, formulation, technique, exposure time and individual skin characteristics
Clinical purpose To promote progressive epidermal renewal within personalised treatment protocols
________________________________________
BIOLOGICAL BASIS
The clinical behaviour of a chemical peel depends on the biological response developed by the epidermis following application of the active ingredient and not exclusively on its nominal concentration.
In the case of Pyruvic Acid, its interaction with the stratum corneum promotes the progressive reorganisation of the epidermal surface through physiological mechanisms that contribute to improving skin texture, optimising skin balance and enhancing Skin Quality.
Treatment progression will depend on each patient’s biological response capacity, the functional condition of the skin and the correct clinical planning carried out by the professional.
For this reason, interpreting the mechanism of action requires integrating scientific knowledge with clinical observation, allowing each treatment protocol to be adapted to the specific biological progression of each patient.
________________________________________
SCIENTIFIC PRINCIPLES OF USE
Interpretation of the mechanism of action should be based on several fundamental principles:
✔ the biological response is always individual;
✔ concentration alone does not determine clinical behaviour;
✔ skin barrier function influences treatment tolerance and progression;
✔ the physiological condition of the stratum corneum influences the clinical response;
✔ treatment planning is more important than the isolated intensity of each treatment session;
✔ clinical reassessment allows treatment to be adapted according to the observed progression;
✔ the quality of the outcome depends on the combination of diagnosis, indication and correct execution of the procedure.
________________________________________
THERAPDERMA CONCLUSION
Understanding the mechanism of action of Pyruvic Peel 30% means understanding how the skin responds to carefully controlled progressive chemical exfoliation.
Its effectiveness does not depend exclusively on the concentration of the acid, but on the interaction between the formulation, the pH, the application technique and the biological characteristics of each patient.
This perspective makes it possible to interpret the clinical response from a scientific standpoint, promoting more precise, personalised treatment protocols that are consistent with skin physiology.
Integrated into the TherapDerma Clinical Ecosystem™, this knowledge provides the foundation for incorporating Pyruvic Peel 30% into therapeutic strategies aimed at optimising Skin Quality, regulating excess sebum and progressively improving skin texture, while always respecting each patient’s individual biological progression.
Scientific Foundations
The formulation determines clinical performance
In a professional chemical peel, the acid concentration represents only one of the many factors involved in the skin’s biological response.
The clinical performance of a formulation depends on the interaction between its physicochemical properties, the functional availability of the active ingredient, the application technique and the individual biological characteristics of each patient.
For this reason, formulations that appear similar may exhibit different clinical profiles, even when they contain the same nominal concentration of the acid.
From this perspective, Pyruvic Peel 30% TherapDerma has been developed to be integrated into professional protocols in which the complete formulation constitutes an essential element for achieving a predictable, reproducible clinical response consistent with skin physiology.
The scientific interpretation of a chemical peel should always consider all these factors and not solely the declared percentage of the active ingredient.
________________________________________
CONCENTRATION
An important parameter, but never sufficient on its own
Concentration expresses the nominal amount of Pyruvic Acid present in the formulation, but by itself it does not determine the intensity or clinical behaviour of the procedure.
Two peels with the same concentration may produce different responses when variations exist in pH, vehicle, formulation stability, exposure time or the physiological condition of the skin.
Therefore, concentration should be interpreted as one of the parameters guiding the clinical selection of treatment, always within the context of a complete professional assessment.
In Pyruvic Peel 30%, the concentration of the active ingredient has been selected to support protocols for progressive epidermal renewal, regulation of excess sebum, improvement of skin texture and optimisation of Skin Quality, while respecting each patient’s individual biological progression.
________________________________________
THE ROLE OF pH
A regulator of chemical balance
pH is one of the most relevant physicochemical parameters in the design of a professional chemical peel.
Beyond indicating the acidity of the formulation, it participates in the chemical balance of the acid and influences the proportion of functionally available molecules during the procedure.
Small variations in pH may modify the clinical behaviour of formulations with a similar nominal concentration, influencing the interaction of the active ingredient with the stratum corneum.
For this reason, pH represents one of the principal regulators of formulation behaviour and contributes to the predictability, reproducibility and safety of the clinical procedure.
________________________________________
THE SIGNIFICANCE OF pKa
Understanding the chemical equilibrium of Pyruvic Acid
pKa is a physicochemical property specific to each acid and describes the equilibrium between its ionised and non-ionised forms according to the pH of the medium.
Pyruvic Acid has a characteristic dissociation constant (pKa ≈ 2.50), inherent to its molecular structure.
This value helps explain how the chemical availability of the active ingredient may vary among different formulations, although it does not by itself predict the clinical response obtained.
Its true scientific value lies in facilitating the interpretation of the formulation’s chemical behaviour when analysed together with pH, application technique and the biological characteristics of the skin.
________________________________________
PHYSICOCHEMICAL PROFILE OF PYRUVIC ACID
Scientific characteristics of the active ingredient
Pyruvic Acid belongs to the family of alpha-keto acids (α-keto acids) and is a physiological intermediate involved in cellular energy metabolism.
Chemically, it is a water-soluble alpha-keto acid whose molecular structure supports its use in formulations intended for progressive epidermal renewal and optimisation of skin quality.
These properties, combined with a professionally developed formulation, contribute to promoting controlled exfoliation, improving superficial skin texture, regulating excess sebum and progressively optimising Skin Quality.
SCIENTIFIC MOLECULAR PROFILE™
Parameter Value
Chemical name Pyruvic Acid
Chemical family Alpha-keto acid (α-keto acid)
Molecular formula C₃H₄O₃
Molecular weight 88.06 g/mol
Chemical nature Water-soluble alpha-keto acid
pKa ≈ 2.50
Primary site of action Stratum corneum
Type of exfoliation Progressive chemical exfoliation
The clinical relevance of these characteristics lies not only in their molecular properties, but also in the interaction between the active ingredient, the complete formulation and skin biology, making it possible to develop professional protocols based on controlled exfoliation, progressive epidermal renewal and gradual optimisation of Skin Quality.
________________________________________
WHY CAN TWO PEELS BEHAVE DIFFERENTLY?
Much more than acid concentration
Although two peels may share the same active ingredient or an apparently similar nominal concentration, their clinical behaviour may differ significantly.
The biological response observed during the procedure depends on the simultaneous interaction of physicochemical, technical and biological factors that influence the functional availability of the active ingredient and its interaction with the epidermis.
Among the main variables influencing this behaviour are:
✔ nominal concentration of Pyruvic Acid;
✔ formulation pH;
✔ chemical equilibrium determined by pKa;
✔ vehicle and excipient composition;
✔ formulation stability;
✔ professional application technique;
✔ number of layers applied;
✔ effective exposure time;
✔ functional condition of the skin barrier;
✔ hydration of the stratum corneum;
✔ individual biological sensitivity.
For this reason, the scientific interpretation of a chemical peel should always consider the overall interaction of all these factors rather than the acid concentration in isolation.
________________________________________
THE VEHICLE AND THE FORMULATION
The invisible architecture of the peel
In addition to the active ingredient, every formulation includes a vehicle and a set of excipients that determine how the product is distributed across the skin and maintains its stability during the procedure.
These components influence application uniformity, the functional availability of Pyruvic Acid and the clinical reproducibility of the treatment.
A properly developed formulation promotes more stable, homogeneous and predictable performance, allowing consistent results within standardised professional protocols.
From a scientific perspective, the formulation should therefore be understood as a complete system rather than simply an acid concentration.
________________________________________
EXPOSURE TIME
A variable that must be individualised
The time during which the formulation remains in contact with the skin is one of the clinical factors that most strongly influences the progression of the procedure.
Its duration should always be determined according to the diagnosis, treatment area, thickness of the stratum corneum, observed tolerance and the clinical response obtained during the session.
There is no universal exposure time applicable to every patient.
Continuous observation of the skin response makes it possible to adjust the procedure whenever necessary, promoting greater safety and more predictable clinical outcomes.
________________________________________
SKIN BARRIER FUNCTION
The foundation of an appropriate physiological response
The integrity of the skin barrier is one of the principal determinants of tolerance and biological response to any chemical peel.
A functional skin barrier helps maintain epidermal homeostasis, regulate transepidermal water loss and preserve the physiological balance of the skin surface.
Factors such as hydration of the stratum corneum, environmental exposure, previous treatments or certain dermatological conditions may modify the clinical response to the procedure.
For this reason, the initial assessment of skin barrier function is an essential step in selecting safer protocols adapted to each patient’s specific needs.
________________________________________
BIOLOGICAL VARIABILITY
Every skin responds differently
The biological response to a chemical peel is never identical between two patients.
Age, phototype, epidermal hydration, thickness of the stratum corneum, sebaceous activity, skin sensitivity, environmental exposure and previous therapeutic history may all influence the clinical progression of treatment.
Even when using the same formulation and following exactly the same protocol, the physiological response may differ significantly.
For this reason, every procedure should be adapted according to the observed clinical progression through continuous reassessment throughout the treatment.
________________________________________
FACTORS THAT MODIFY THE CLINICAL RESPONSE
An integrated view of the procedure
FORMULATION
✔ Active ingredient concentration.
✔ pH.
✔ pKa.
✔ Vehicle and excipients.
✔ Physicochemical stability.
↓
PROCEDURE
✔ Skin preparation.
✔ Application technique.
✔ Number of layers.
✔ Exposure time.
✔ Neutralisation when indicated.
↓
PATIENT
✔ Skin barrier function.
✔ Epidermal hydration.
✔ Phototype.
✔ Individual sensitivity.
✔ Clinical diagnosis.
↓
BIOLOGICAL RESPONSE
↓
CLINICAL OUTCOME
This integrated interpretation makes it possible to develop safer, more reproducible and more personalised protocols, adapting each procedure to the observed biological progression and promoting results consistent with skin physiology.
________________________________________
SCIENCE AT A GLANCE™
Parameter Pyruvic Peel 30%
Active ingredient Pyruvic Acid
Concentration 30%
Site of action Stratum corneum
Type of exfoliation Progressive chemical exfoliation
Predominant mechanism Progressive reduction in cohesion between corneocytes
Main physiological process Epidermal renewal and reorganisation of the stratum corneum
Expected physiological outcome Regulation of excess sebum and optimisation of Skin Quality
Key clinical variables Formulation, pH, pKa, application technique, exposure time and individual biological response
Clinical purpose To promote progressive epidermal renewal within personalised professional protocols
________________________________________
SCIENTIFIC FORMULATION PROFILE™
Technical characteristics of the formulation
Parameter Pyruvic Peel 30%
Active ingredient Pyruvic Acid
Chemical family Alpha-keto acid (α-keto acid)
Molecular formula C₃H₄O₃
Molecular weight 88.06 g/mol
Chemical nature Water-soluble alpha-keto acid
pKa ≈ 2.50
Physiological origin Intermediate of cellular metabolism
Professional presentation 50 mL
Intended use Professional use only
Note: The clinical behaviour of the formulation will always depend on the interaction between its physicochemical properties, the treatment protocol applied and the individual biological characteristics of each patient.
________________________________________
NEUTRALISATION
Restoring physiological balance
Neutralisation is an essential stage whenever required by the protocol of the peel being used.
Its purpose is to interrupt the activity of the formulation in a controlled manner, promoting the progressive restoration of the physiological balance of the skin surface and initiating the epidermal recovery phase.
The decision to neutralise should be based on the professional protocol, the effective exposure time and the clinical response observed during the session.
When correctly performed, neutralisation contributes to improving the safety, reproducibility and predictability of the procedure.
________________________________________
APPLICATION OF SCIENTIFIC KNOWLEDGE
From the laboratory to clinical practice
Understanding the physicochemical properties of a formulation makes it possible to interpret more precisely the behaviour of the peel during the clinical procedure.
Integrating this information with patient assessment facilitates selection of the most appropriate treatment protocol, progressive treatment adjustment and optimisation of the observed biological response.
In this way, scientific evidence ceases to be merely theoretical knowledge and becomes a practical tool supporting clinical decision-making.
________________________________________
SCIENTIFIC NOTE
The physicochemical properties of a formulation help to understand its potential behaviour but never replace the clinical assessment performed by the professional.
Treatment progression will always depend on the interaction between the formulation, the application technique and each patient’s individual biological response.
________________________________________
THERAPDERMA SCIENTIFIC INSIGHT™
Correctly interpreting a formulation means understanding how the chemistry of the active ingredient, the complete formulation and skin biology interact throughout the entire procedure.
This scientific perspective makes it possible to develop safer, more reproducible and physiologically consistent protocols, promoting therapeutic strategies aimed at improving skin texture, regulating excess sebum and progressively optimising Skin Quality.
________________________________________
THERAPDERMA CONCLUSION
The true strength of a professional chemical peel does not lie exclusively in the concentration of the active ingredient, but in the professional’s ability to interpret the overall behaviour of the formulation and adapt each procedure to each patient’s specific biological response.
Integrating physicochemical knowledge with clinical assessment makes it possible to develop more precise, safer and more reproducible protocols while consistently respecting skin physiology and the individual’s treatment progression.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% is a therapeutic tool designed to integrate into clinical strategies aimed at regulating excess sebum, progressively improving skin texture and optimising Skin Quality, combining scientific evidence, individualised diagnosis and personalised therapeutic planning.
Indications
When should Pyruvic Peel 30% be selected?
The indication for a professional chemical peel should always be based on a comprehensive clinical diagnosis and the definition of specific therapeutic objectives.
Beyond the acid concentration, the decision depends on the biological characteristics of the skin, the condition of the skin barrier and the clinical outcomes to be achieved.
Within this context, Pyruvic Peel 30% may be incorporated when the professional considers progressive epidermal renewal appropriate to improve skin texture, promote the balance of excess sebum, optimise the appearance of pores and enhance Skin Quality, always within properly planned personalised protocols.
Each indication should be established individually, avoiding standardised protocols and adapting treatment according to each patient’s clinical progression.
________________________________________
PATIENT PROFILE
Which characteristics are commonly observed?
Pyruvic Peel 30% may be considered in patients presenting with superficial alterations that may benefit from progressive epidermal renewal and improved Skin Quality.
These patients frequently present one or more of the following characteristics:
✔ oily or seborrhoeic skin;
✔ excess sebaceous secretion;
✔ enlarged pores;
✔ irregular skin texture;
✔ appropriately selected acne-prone skin;
✔ superficial post-acne marks;
✔ early signs of photoageing;
✔ the need to improve overall skin quality.
The presence of one or more of these characteristics does not, by itself, constitute an automatic indication. The final decision will always depend on the professional assessment and the established therapeutic plan.
________________________________________
MAIN CLINICAL INDICATIONS
Pyruvic Peel 30% may be incorporated into professional protocols aimed at:
✔ oily or seborrhoeic skin;
✔ excess sebum;
✔ enlarged pores;
✔ irregular superficial skin texture;
✔ acne-prone skin;
✔ superficial post-acne marks;
✔ progressive improvement of Skin Quality;
✔ Skin Quality programmes.
Each of these indications requires specific planning and may be integrated into different therapeutic strategies.
________________________________________
OILY SKIN OR EXCESS SEBUM
Increased sebaceous activity may lead to persistently shiny skin, more visible pores and a less even skin texture.
In these cases, Pyruvic Peel 30% may form part of protocols designed to progressively promote balance of the skin surface.
The usual objectives include:
✔ regulating excess sebum;
✔ promoting a more balanced-looking complexion;
✔ improving superficial skin texture;
✔ optimising Skin Quality;
✔ promoting a healthier appearance.
The protocol should always be adapted according to the clinical characteristics observed in each patient.
________________________________________
ENLARGED PORES AND SUPERFICIAL IMPERFECTIONS
Visible pores and superficial imperfections may be associated with excess sebaceous secretion, less efficient epidermal renewal and the accumulation of corneocytes.
When these alterations are predominantly superficial, Pyruvic Peel 30% may be integrated into protocols aimed at promoting a more even appearance of the skin.
Before establishing the indication, the professional should assess:
✔ the origin of the alteration;
✔ distribution of the lesions;
✔ phototype;
✔ skin barrier condition;
✔ previous treatments;
✔ treatment objectives.
Treatment planning should always be accompanied by appropriate clinical follow-up and the recommended home care programme.
________________________________________
IRREGULAR SKIN TEXTURE
Alterations of the skin microrelief may be associated with physiological ageing, photoexposure or less efficient epidermal renewal.
When these alterations are predominantly superficial, Pyruvic Peel 30% may be incorporated into protocols designed to promote a visually more even complexion.
Clinical objectives may include:
✔ improving skin texture;
✔ smoothing the skin microrelief;
✔ promoting a more homogeneous skin surface;
✔ optimising the appearance of pores;
✔ optimising Skin Quality.
________________________________________
EARLY PHOTOAGEING
The early signs of photoageing commonly manifest as irregular texture, loss of uniformity and reduced overall skin quality.
In appropriately selected patients, Pyruvic Peel 30% may form part of programmes designed to progressively improve these superficial changes.
The usual objectives include:
✔ improving skin texture;
✔ promoting a more even appearance;
✔ optimising the appearance of pores;
✔ progressively improving Skin Quality;
✔ promoting a renewed-looking complexion.
Clinical progression will depend on treatment consistency, daily photoprotection and adherence to the recommended home care programme.
________________________________________
ACNE-PRONE SKIN
In appropriately selected patients, acne-prone skin may benefit from protocols designed to promote epidermal renewal and progressively improve the quality of the skin surface.
Within carefully planned protocols, Pyruvic Peel 30% may contribute to optimising the balance of excess sebum, improving skin texture and promoting a more even appearance.
The indication should always be established following an individual clinical assessment while respecting the specific characteristics of each patient.
________________________________________
CLINICAL TREATMENT OBJECTIVES
The selection of Pyruvic Peel 30% should always be based on clearly defined clinical objectives before initiating the treatment protocol.
Among the most common objectives are:
✔ optimising Skin Quality;
✔ regulating excess sebum;
✔ promoting a more even skin texture;
✔ improving the appearance of pores;
✔ optimising the visual uniformity of the skin;
✔ complementing professional Skin Quality programmes;
✔ promoting progressive epidermal renewal.
Clearly defining the objectives beforehand facilitates treatment planning and allows a more accurate assessment of clinical progression.
________________________________________
CRITERIA FOR SELECTING PYRUVIC PEEL 30%
The decision to use Pyruvic Peel 30% should be based on the overall patient assessment and the correlation between the observed clinical characteristics and the established therapeutic objectives.
Before indicating Pyruvic Peel 30%, it is advisable to confirm:
✔ that the alterations to be treated are predominantly superficial;
✔ that there is a clearly defined clinical indication;
✔ that the patient understands the treatment objectives;
✔ that appropriate follow-up can be provided;
✔ that the selected protocol is consistent with the expected clinical progression.
Concentration is only one of the elements involved in therapeutic planning and should never be considered an isolated decision-making criterion.
________________________________________
WHEN SHOULD PYRUVIC PEEL 30% BE SELECTED?
Pyruvic Peel 30% may represent an excellent option when the primary objective is to:
✔ regulate excess sebum;
✔ improve skin texture;
✔ optimise the appearance of pores;
✔ promote progressive epidermal renewal;
✔ develop Skin Quality programmes;
✔ complement skin rejuvenation protocols;
✔ maintain a therapeutic strategy that respects skin physiology.
The decision should always be based on the clinical diagnosis and the therapeutic objectives established for each patient.
________________________________________
SUMMARY OF THE MAIN INDICATIONS
Pyruvic Peel 30% may be considered within professional protocols intended for patients presenting with:
✔ oily or seborrhoeic skin;
✔ excess sebum;
✔ enlarged pores;
✔ irregular superficial skin texture;
✔ acne-prone skin;
✔ superficial post-acne marks;
✔ reduced Skin Quality;
✔ the need for Skin Quality programmes.
These indications provide general clinical guidance and should always be interpreted within the context of the individual assessment performed by the professional.
________________________________________
THERAPDERMA CLINICAL CONCLUSION
Correct indication is one of the factors that most strongly influences treatment safety, therapeutic consistency and clinical satisfaction.
Pyruvic Peel 30% has been developed to integrate into professional protocols intended for patients who may benefit from progressive epidermal renewal aimed at regulating excess sebum, improving skin texture, optimising the appearance of pores and enhancing Skin Quality.
The decision to use this peel should be based on a rigorous clinical assessment, clearly defined therapeutic objectives and an individualised treatment plan adapted to each patient’s clinical progression.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% represents a clinical tool designed to integrate into personalised Skin Quality programmes, promoting professional practice based on scientific evidence, individualised treatment and respect for skin physiology.
Contraindications
Safety begins before treatment
The decision to perform a professional chemical peel does not depend solely on the existence of a clinical indication. Before initiating any procedure, it is essential to identify situations that may compromise patient safety or modify the expected response to treatment.
Early identification of contraindications helps reduce the risk of complications, determine the most appropriate time to intervene or, when necessary, select a different therapeutic strategy.
Safe clinical practice is not only about knowing when to treat, but also about recognising when it is preferable to postpone or avoid the procedure.
________________________________________
ABSOLUTE CONTRAINDICATIONS
The following situations contraindicate the use of Pyruvic Peel 30% until the underlying cause has resolved or a new clinical assessment allows the treatment to be reconsidered.
________________________________________
PREGNANCY AND BREASTFEEDING
As a precautionary measure, chemical peels are not recommended during pregnancy or while breastfeeding.
Although the systemic absorption of topically applied Pyruvic Acid is very limited, there are insufficient clinical data to support its routine use during these periods.
Patient safety should always take precedence over any aesthetic objective.
________________________________________
ACTIVE SKIN INFECTIONS
Pyruvic Peel 30% should not be applied to skin presenting with active infectious processes, as inflammation and tissue alteration may modify the skin’s behaviour during the procedure.
The main situations include:
✔ active herpes simplex;
✔ bacterial infections;
✔ viral infections;
✔ fungal infections;
✔ pustular lesions of infectious origin;
✔ any inflammatory process associated with infection.
Treatment may only be reconsidered once the infectious process has completely resolved and the skin has regained its clinical integrity.
________________________________________
WOUNDS AND IMPAIRED SKIN INTEGRITY
The procedure should not be performed on areas presenting visible alterations of the skin surface.
This includes:
✔ open wounds;
✔ abrasions;
✔ erosions;
✔ fissures;
✔ excoriations;
✔ recent burns;
✔ sunburn;
✔ areas subjected to surgical or traumatic procedures with incomplete healing.
The skin should be fully recovered before any chemical exfoliation procedure is considered.
________________________________________
ACTIVE INFLAMMATORY DERMATOSES
The presence of active inflammatory skin diseases within the treatment area temporarily contraindicates the procedure.
These include:
✔ dermatitis;
✔ eczema;
✔ active psoriasis;
✔ inflammatory rosacea;
✔ contact dermatitis;
✔ uncontrolled seborrhoeic dermatitis;
✔ other dermatoses associated with inflammation or epidermal disruption.
The procedure may only be reconsidered once the condition has stabilised and the clinical assessment confirms skin recovery.
________________________________________
HYPERSENSITIVITY TO THE FORMULATION
Pyruvic Peel 30% is contraindicated in patients with a known history of hypersensitivity to Pyruvic Acid or to any component of the formulation.
In the presence of any history of allergic reactions, significant intolerance or unexpected responses to similar procedures, an individual assessment should be carried out before considering treatment.
Previous experience with other exfoliating acids does not necessarily imply an equivalent response to Pyruvic Acid.
________________________________________
EXTREMELY REACTIVE SKIN
In patients with a marked tendency to develop exaggerated skin responses, the professional should carefully assess the suitability of the procedure.
Particularly where there is a history of:
✔ persistent irritation;
✔ recurrent episodes of dermatitis;
✔ intolerance to multiple cosmetic products;
✔ severe reactions following superficial procedures;
✔ disproportionate skin sensitivity.
In these cases, it may be preferable to stabilise the skin first or to select an alternative therapeutic strategy according to clinical judgement.
________________________________________
TEMPORARY CONTRAINDICATIONS
Certain circumstances do not permanently contraindicate the use of Pyruvic Peel 30%, but make it advisable to delay the procedure until the skin has recovered its normal physiological condition.
The decision should always be based on the observed clinical progression rather than solely on a predetermined time interval.
________________________________________
RECENT DERMATOLOGICAL OR AESTHETIC TREATMENTS
Before indicating the peel, it is essential to determine which procedures have been performed during the preceding weeks, as some may temporarily modify the skin’s response.
Particular attention should be paid to patients who have recently undergone:
✔ topical or oral retinoid treatment;
✔ other exfoliating agents;
✔ keratolytic treatments;
✔ laser procedures;
✔ skin resurfacing;
✔ dermabrasion or microdermabrasion;
✔ microneedling;
✔ other chemical peels.
The use of Pyruvic Peel 30% should be postponed until complete skin recovery has been confirmed and no clinical signs of residual irritation remain.
________________________________________
HAIR REMOVAL AND PROCEDURES THAT INCREASE SKIN SENSITIVITY
Certain cosmetic techniques may temporarily alter the skin surface and increase sensitivity to the procedure.
These include:
✔ waxing;
✔ thread hair removal;
✔ depilatory creams;
✔ electrolysis;
✔ particularly aggressive shaving;
✔ intensive extractions;
✔ similar procedures that may sensitise the skin.
Treatment should be postponed until the treated area has completely returned to its normal condition.
________________________________________
RECENT SUN EXPOSURE
It is not advisable to initiate a treatment protocol when the skin shows signs of intense sun exposure, solar erythema or a recent tan.
Likewise, the procedure should be postponed if the patient anticipates significant sun exposure during the recovery period and cannot ensure adequate photoprotection.
Treatment scheduling should always be adapted to the individual clinical circumstances of each patient.
________________________________________
SITUATIONS REQUIRING SPECIFIC CLINICAL ASSESSMENT
Certain circumstances do not constitute an absolute contraindication but require a more detailed evaluation before deciding whether to perform the procedure.
These include:
✔ a history of post-inflammatory hyperpigmentation;
✔ a tendency towards hypertrophic or keloid scarring;
✔ systemic diseases that may affect skin repair;
✔ pharmacological treatments influencing the skin’s response;
✔ previous severe reactions to aesthetic procedures;
✔ medical conditions requiring additional assessment.
In these cases, the treatment protocol should be individualised after carefully evaluating the balance between the expected benefit and the potential clinical risk.
________________________________________
PHARMACOLOGICAL TREATMENTS
Reviewing the patient’s regular medication forms part of the pre-treatment assessment.
Particular attention should be given to medicines that may:
✔ increase photosensitivity;
✔ modify the inflammatory response;
✔ impair wound healing;
✔ interfere with the normal processes of skin recovery.
Whenever there is uncertainty regarding the compatibility of pharmacological treatment with the procedure, it is advisable to obtain an assessment from the responsible healthcare professional before proceeding.
________________________________________
PATIENT COMPLIANCE
The safety of the procedure also depends on the patient’s ability to follow professional recommendations correctly.
Treatment should be reconsidered where there is a high likelihood of non-compliance with essential aspects such as:
✔ post-treatment care;
✔ daily use of photoprotection;
✔ scheduled follow-up appointments;
✔ instructions relating to home care products.
Active patient cooperation is an essential element in minimising risks and promoting appropriate clinical progression.
________________________________________
PRE-PROCEDURE CLINICAL CHECKLIST
Before performing Pyruvic Peel 30%, it is recommended to confirm that all essential safety criteria have been verified.
☐ The skin is intact and free from visible lesions.
☐ There are no signs of active skin infection.
☐ There are no inflammatory dermatoses in the treatment area.
☐ The patient is not pregnant or breastfeeding.
☐ There is no known history of hypersensitivity to the formulation.
☐ Recent medical and aesthetic treatments have been reviewed.
☐ There has been no recent sun exposure that may interfere with the procedure.
☐ The risk of pigmentary alterations has been assessed where appropriate.
☐ The patient understands the recommendations before and after treatment.
☐ There is a clearly established clinical indication.
☐ All the necessary materials are available to perform the procedure according to the professional protocol.
A systematic assessment before every treatment session contributes to maintaining a high level of safety and promotes more consistent clinical decision-making.
________________________________________
CLINICAL DECISION-MAKING WHEN A CONTRAINDICATION IS IDENTIFIED
Identifying a contraindication does not always mean the treatment must be permanently cancelled.
Depending on the clinical situation, the professional may choose one of the following approaches:
POSTPONE THE PROCEDURE
When the identified condition is temporary and may resolve over time or following the skin’s physiological recovery.
MODIFY THE THERAPEUTIC STRATEGY
When another alternative is more appropriate for the patient’s clinical characteristics or treatment objectives.
REQUEST MEDICAL ASSESSMENT
When diseases, pharmacological treatments or clinical circumstances require further evaluation before proceeding.
DO NOT PERFORM THE PROCEDURE
When the potential risk clearly outweighs the expected benefit or appropriate safety conditions cannot be guaranteed.
The decision not to treat, when clinically justified, is also part of responsible professional practice.
________________________________________
PRINCIPLES OF CLINICAL SAFETY
The prevention of complications begins long before the peel is applied.
A thorough clinical assessment makes it possible to:
✔ identify risk factors before treatment;
✔ select the most appropriate time to intervene;
✔ adapt the therapeutic strategy to the patient’s characteristics;
✔ reduce the likelihood of undesirable responses;
✔ promote safer and more predictable procedures.
Safety should be understood as a continuous process that accompanies every stage of treatment, from the initial consultation to the final evaluation of the results.
________________________________________
THERAPDERMA CONCLUSION
The identification of contraindications is one of the fundamental pillars of safe clinical practice in professional chemical peels.
Before each treatment session, the professional should confirm that the skin meets the appropriate conditions for treatment and that the expected benefits fully justify the procedure.
Recognising the appropriate time to treat, postpone or even avoid a procedure forms part of responsible clinical decision-making and represents an essential element in minimising risks and promoting predictable clinical progression.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% is integrated into a model of care based on individual patient assessment, complication prevention and the rigorous application of evidence-based treatment protocols.
Professional Application
A procedure based on precision, clinical observation and personalisation
The quality of a professional chemical peel does not depend solely on the formulation used, but also on the way each treatment session is planned, performed and monitored.
Each treatment must be adapted to the individual characteristics of the skin, the anatomical area being treated and the skin response observed during the procedure.
Pyruvic Peel 30% has been developed exclusively for professional use and should be applied following a structured protocol, in which every stage contributes to ensuring a safe, precise procedure that respects skin physiology.
Appropriate patient preparation, a consistent application technique and continuous observation of clinical progression constitute the pillars of controlled and reproducible professional practice.
________________________________________
PATIENT PREPARATION
Preparation begins before the day of the treatment session and aims to create the most favourable conditions for carrying out the procedure.
According to the clinical assessment and the patient’s individual characteristics, the professional may temporarily recommend:
✔ avoiding intense sun exposure;
✔ maintaining appropriate daily photoprotection;
✔ discontinuing, where appropriate, potentially irritating cosmetic products;
✔ avoiding physical or chemical exfoliants;
✔ avoiding procedures that may sensitise the skin before the treatment session;
✔ maintaining a gentle home care routine compatible with the treatment;
✔ reporting any significant changes in the condition of the skin before the procedure.
These recommendations should be individualised and adapted to each patient’s needs.
Before starting the treatment session, it is essential to confirm that the skin is stable and meets the appropriate conditions for treatment.
________________________________________
SKIN PREPARATION
Proper preparation facilitates even application of the peel and allows greater control throughout the procedure.
Before beginning, the professional should:
✔ thoroughly cleanse the treatment area;
✔ remove make-up, sunscreen and other cosmetic residues;
✔ eliminate superficial impurities;
✔ degrease the skin only when indicated by the treatment protocol;
✔ completely dry the skin surface;
✔ confirm that there are no visible lesions incompatible with the procedure.
All preparation should be carried out gently, avoiding manoeuvres that may unnecessarily increase skin sensitivity.
________________________________________
PROTECTION OF SENSITIVE AREAS
Before applying Pyruvic Peel 30%, it is advisable to identify any areas requiring specific protection in order to minimise the risk of accidental contact.
These may include:
✔ the eye contour;
✔ the lips and mucous membranes;
✔ the corners of the mouth;
✔ the nasal alae;
✔ skin folds;
✔ recently treated areas;
✔ particularly sensitive areas.
Protection should be applied precisely, avoiding interference with the treatment area.
The professional should also prevent the product from coming into contact with the eyes, mucous membranes or any area not included within the treatment protocol.
________________________________________
APPLICATION OF THE PEEL
Pyruvic Peel 30% should be applied evenly and systematically, strictly following the established professional protocol.
Throughout the procedure, continuous monitoring is essential for:
✔ even distribution of the product;
✔ the quantity applied to each area;
✔ the application sequence;
✔ contact time;
✔ the observed skin response;
✔ the patient’s reported comfort.
The technique should always be adapted to the individual’s skin characteristics and should never be reproduced automatically for every patient.
________________________________________
APPLICATION SEQUENCE AND UNIFORMITY
Following a predefined working sequence helps maintain precise control of the procedure and ensures a consistent exposure time across all treated areas.
It is recommended to:
✔ begin with the areas indicated in the professional protocol;
✔ maintain a uniform quantity of product;
✔ avoid accumulation in skin folds or depressions;
✔ monitor proximity to mucous membranes and protected areas;
✔ continuously observe the response of each treated area.
A well-organised application allows adjustments to be made during the treatment session whenever clinical progression indicates they are necessary.
________________________________________
CONTROL OF EXPOSURE TIME
Exposure time is one of the most important variables of the procedure and should be determined according to the professional protocol and the clinical progression observed during the treatment session.
The professional should consider:
✔ the anatomical treatment area;
✔ the clinical characteristics of the skin;
✔ the patient’s tolerance;
✔ the skin response during application.
The planned maximum exposure time should be regarded as a safety limit and not as a target that must necessarily be reached.
Whenever clinical progression indicates, neutralisation should be performed before the initially planned time.
Under no circumstances should exposure be prolonged with the aim of obtaining a more intense response.
________________________________________
CLINICAL OBSERVATION DURING THE TREATMENT SESSION
The skin response may vary between patients and even between different areas of the same individual.
For this reason, clinical observation should continue throughout the entire procedure.
The professional should pay particular attention to:
✔ the appearance of erythema;
✔ sensations of warmth or stinging reported by the patient;
✔ uniformity of the response;
✔ possible differences between anatomical regions;
✔ any changes indicating that the procedure should be modified or concluded.
The observed clinical progression should always take priority over the initial treatment plan.
________________________________________
CRITERIA FOR COMPLETING THE APPLICATION
The application should be discontinued when:
✔ the planned clinical response has been achieved;
✔ the protocol-established exposure time has been completed;
✔ the patient experiences significant discomfort;
✔ an excessive or unexpected response occurs;
✔ the professional considers that continuing may increase the risk.
Concluding the procedure at the appropriate time is an essential part of responsible clinical practice.
________________________________________
NEUTRALISATION
Neutralisation is an essential stage of the procedure and should be carried out exclusively using the neutralising solution recommended by TherapDerma.
Its purpose is to stop the activity of the peel and allow precise control of the treatment intensity.
Once the neutralising solution has been applied, the professional should:
✔ cover the entire treated surface evenly;
✔ pay particular attention to folds and areas where product may accumulate;
✔ completely remove the product according to the established protocol;
✔ immediately reassess the skin response before proceeding with post-treatment care.
Neutralisation performed at the appropriate moment is an essential element in ensuring safety, treatment consistency and appropriate clinical progression.
________________________________________
IMMEDIATE POST-TREATMENT CARE
Once neutralisation has been completed and the product has been fully removed, the next objective is to restore skin comfort and support the physiological recovery process.
According to the observed response, the professional may apply the post-procedure products included within the TherapDerma protocol and recommend the most appropriate home care measures.
It is recommended to:
✔ use gentle cleansing products;
✔ apply the recommended repairing products;
✔ maintain appropriate skin hydration;
✔ use a broad-spectrum sunscreen daily;
✔ avoid direct sun exposure during the recovery period;
✔ temporarily discontinue potentially irritating cosmetic products;
✔ avoid exfoliants and other procedures until the skin has completely recovered;
✔ report any unexpected reactions.
Post-treatment care forms part of the overall treatment and contributes to gradual, controlled recovery while respecting skin physiology.
________________________________________
CLINICAL PROGRESSION AND FOLLOW-UP
Professional assessment does not end with the final application of the peel.
During the following days, clinical progression may vary between patients depending on the individual’s skin characteristics and the response obtained during the treatment session.
During the follow-up assessment, the professional should evaluate:
✔ skin progression;
✔ tolerance of the procedure;
✔ physiological recovery of the epidermis;
✔ the presence or absence of desquamation;
✔ changes observed in skin texture, excess sebum and the appearance of pores;
✔ the need to adapt the home care programme;
✔ whether it is appropriate to schedule another treatment session.
Each treatment should be reassessed individually before continuing with the therapeutic protocol.
________________________________________
GOOD PROFESSIONAL PRACTICE
The application of Pyruvic Peel 30% should form part of an organised and standardised clinical methodology.
The following principles are always recommended:
✔ follow the TherapDerma professional protocol;
✔ respect the product’s technical instructions;
✔ adapt the procedure to each patient;
✔ continuously observe the clinical response;
✔ maintain constant communication with the patient;
✔ document each treatment session appropriately;
✔ reassess before scheduling further procedures.
A systematic methodology and precise technique contribute to improving the safety, reproducibility and clinical consistency of every treatment.
________________________________________
MISTAKES TO AVOID
During the professional use of Pyruvic Peel 30%, particular care should be taken to avoid:
✘ applying exactly the same procedure to every patient;
✘ using an excessive quantity of product;
✘ allowing product to accumulate in skin folds or sensitive areas;
✘ unnecessarily prolonging the exposure time;
✘ ignoring differences in response between different anatomical regions;
✘ delaying neutralisation when clinical progression indicates that the procedure should be concluded;
✘ combining treatments without respecting the recovery period;
✘ omitting home care recommendations;
✘ initiating further treatment sessions without prior clinical reassessment.
Preventing these errors forms part of responsible clinical practice and is one of the principal factors in maintaining procedural safety.
________________________________________
PROFESSIONAL CHECKLIST
Before concluding the procedure, confirm that:
☐ The product was applied evenly.
☐ The professional protocol was followed.
☐ Neutralisation was performed correctly.
☐ The product was completely removed.
☐ The immediate skin response was assessed.
☐ The indicated post-procedure care was applied.
☐ The patient received clear home care instructions.
☐ The treatment session was properly documented.
☐ A clinical review was scheduled where appropriate.
A systematic verification at the end of every treatment session supports continuity of care, facilitates clinical follow-up and contributes to maintaining high professional standards.
________________________________________
THERAPDERMA CONCLUSION
The correct application of a professional chemical peel requires much more than an appropriate technique. It demands planning, continuous clinical observation and the ability to adapt every decision according to the individual’s skin response.
Pyruvic Peel 30% has been developed to integrate into structured professional protocols, where every stage—from initial preparation to clinical follow-up—contributes to maintaining high standards of safety, technical precision and therapeutic consistency.
At TherapDerma, we understand that clinical excellence is achieved through the combination of scientific knowledge, professional experience and a rigorously planned methodology.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% forms part of a model of care designed to optimise Skin Quality through personalised, reproducible, evidence-based procedures, while respecting skin physiology, the balance of excess sebum and each patient’s individual clinical progression.
Clinical Protocols
Personalised strategies for different therapeutic objectives
Pyruvic Peel 30% may be integrated into different aesthetic medicine programmes whenever there is an appropriate clinical indication and patient selection has been carried out correctly.
There is no single protocol suitable for every case. Treatment planning should be adapted to the biological characteristics of the skin, the established therapeutic objectives and the clinical progression observed between treatment sessions.
The protocols presented below provide general guidance intended to facilitate therapeutic planning and should always be applied according to professional judgement and the official TherapDerma technical instructions.
________________________________________
PROTOCOL FOR OILY SKIN AND EXCESS SEBUM
Objective
To progressively promote the balance of sebaceous secretion, improve skin texture and optimise Skin Quality through controlled epidermal renewal.
Patients who may benefit
✔ oily skin;
✔ excess sebum;
✔ persistent shine;
✔ enlarged pores;
✔ irregular skin texture;
✔ appropriately selected acne-prone skin.
Clinical objectives
• Promote the balance of excess sebum.
• Progressively optimise skin texture.
• Improve the appearance of pores.
• Optimise Skin Quality.
Protocol progression
Treatment continuity should be determined according to the clinical progression observed at each treatment session, adapting the therapeutic strategy whenever necessary.
________________________________________
PROTOCOL FOR ENLARGED PORES AND IRREGULAR SKIN TEXTURE
Objective
To promote a more even skin surface through progressive epidermal renewal programmes aimed at optimising skin texture and microrelief.
May be considered when there is:
✔ enlarged pores;
✔ irregular skin texture;
✔ rough skin surface;
✔ loss of skin uniformity;
✔ excess sebum.
Clinical objectives
• Progressively refine skin texture.
• Promote a more even appearance.
• Improve the appearance of pores.
• Progressively optimise Skin Quality.
________________________________________
PROTOCOL FOR ACNE-PRONE SKIN
Objective
To promote progressive epidermal renewal and contribute to the balance of the skin surface within professional programmes intended for appropriately selected patients.
May be considered when there is:
✔ acne-prone skin;
✔ excess sebum;
✔ enlarged pores;
✔ irregular skin texture;
✔ superficial imperfections.
Clinical objectives
• Promote physiological epidermal renewal.
• Optimise superficial skin texture.
• Contribute to the balance of excess sebum.
• Complement professional Skin Quality programmes.
Clinical progression should always be reassessed progressively before modifying the therapeutic protocol.
________________________________________
PROTOCOL FOR SUPERFICIAL POST-ACNE MARKS
Objective
To progressively promote a more even skin surface through appropriately planned superficial epidermal renewal programmes.
May be considered when there is:
✔ superficial post-acne marks;
✔ irregular skin texture;
✔ visible pores;
✔ reduced skin uniformity;
✔ the need to improve Skin Quality.
Clinical objectives
• Promote a more homogeneous skin texture.
• Progressively improve the appearance of the skin surface.
• Optimise Skin Quality.
• Complement personalised regenerative programmes.
Each treatment session should be reassessed before continuing the protocol in order to adapt treatment according to the observed clinical progression.
________________________________________
PROTOCOL FOR EARLY PHOTOAGEING
Objective
To contribute to the progressive improvement of skin texture, visual uniformity and overall skin quality through an epidermal renewal programme that respects skin physiology.
May be considered when there is:
✔ irregular skin texture;
✔ visible pores;
✔ fine lines;
✔ uneven skin tone;
✔ early signs of photoageing.
Clinical objectives
• Progressively improve skin texture.
• Promote a more even-looking complexion.
• Optimise Skin Quality.
• Complement comprehensive skin rejuvenation programmes.
Treatment should always be integrated into a therapeutic strategy that includes daily photoprotection, home care and clinical follow-up.
________________________________________
ADVANCED SKIN QUALITY PROTOCOL
Objective
To integrate Pyruvic Peel 30% into a comprehensive programme designed to progressively optimise Skin Quality while respecting skin physiology and each patient’s individual clinical progression.
Areas of action
✔ skin texture;
✔ balance of excess sebum;
✔ appearance of pores;
✔ skin uniformity;
✔ revitalisation;
✔ Skin Quality.
Therapeutic integration
Where there is an appropriate clinical indication, Pyruvic Peel 30% may be incorporated together with:
✔ mesotherapy;
✔ PDRN;
✔ biostimulation protocols;
✔ LED therapy;
✔ compatible medical-aesthetic technologies;
✔ professional home care cosmetics.
The combination of procedures should be carefully planned, always respecting physiological recovery periods and the clinical response observed between treatment sessions.
________________________________________
THERAPDERMA™ COMBINED PROTOCOLS
Integration within a comprehensive therapeutic strategy
Where there is an appropriate clinical indication, Pyruvic Peel 30% may be incorporated into multidisciplinary programmes designed to progressively optimise Skin Quality and enhance treatment outcomes through a comprehensive therapeutic approach.
Therapeutic options that may be combined include:
✔ personalised mesotherapy;
✔ PDRN protocols;
✔ biostimulation;
✔ LED therapy;
✔ radiofrequency;
✔ compatible medical-aesthetic technologies;
✔ professional home care cosmetics.
The selection of each procedure should always correspond to a specific clinical objective while respecting skin physiology and each patient’s individual clinical progression.
________________________________________
THERAPDERMA™ CLINICAL LADDER
Individualised treatment selection
The TherapDerma™ Clinical Ladder facilitates selection of the most appropriate therapeutic strategy according to each patient’s clinical needs and progression.
Initial Level
Pyruvic Peel 30%
May be considered when the objective is to:
✔ improve skin texture;
✔ promote the balance of excess sebum;
✔ optimise the appearance of pores;
✔ promote physiological epidermal renewal;
✔ develop Skin Quality programmes.
Therapeutic progression should always reflect the patient’s clinical evolution and never follow a predetermined sequence.
Every clinical decision should be based on periodic reassessment and the established therapeutic objectives.
________________________________________
MAINTENANCE PROTOCOL
Once the therapeutic objectives have been achieved, a maintenance programme may be established according to each patient’s individual needs.
This programme may include:
✔ periodic treatment sessions where clinically indicated;
✔ scheduled clinical reviews;
✔ updating the home skincare routine;
✔ incorporation of complementary procedures;
✔ daily photoprotection;
✔ ongoing Skin Quality programmes.
Maintenance should be individualised according to clinical progression, the biological characteristics of the skin and the objectives achieved during treatment.
________________________________________
PROTOCOL PERSONALISATION
Every patient presents different biological, functional and clinical characteristics.
For this reason, therapeutic planning should be individualised at every treatment session, adapting dynamically to the observed clinical progression.
Personalisation may involve adjusting:
✔ the extent of the treatment area;
✔ exposure time;
✔ the quantity of product;
✔ the treatment sequence;
✔ the frequency of treatment sessions;
✔ combination with other procedures;
✔ home care.
Protocol flexibility allows optimisation of the therapeutic response while maintaining clinical consistency and respect for skin physiology.
________________________________________
CRITERIA FOR MODIFYING OR DISCONTINUING THE PROGRAMME
During follow-up, the therapeutic strategy may be modified whenever clinical progression indicates that this is appropriate.
Situations that may justify adaptation of the protocol include:
✔ slower recovery than anticipated;
✔ prolonged skin sensitivity;
✔ insufficient therapeutic response;
✔ changes in medication or home care routine;
✔ recent sun exposure;
✔ the appearance of new clinical circumstances;
✔ achievement of the therapeutic objectives.
Following the appropriate clinical reassessment, the professional may:
• maintain the initially established protocol;
• increase the interval between treatment sessions;
• integrate complementary procedures;
• temporarily prioritise professional home care cosmetics;
• temporarily or permanently discontinue treatment.
Modifying, adapting or concluding a protocol when the clinical situation requires it constitutes a professional decision based on safety, individualisation and scientific evidence.
________________________________________
THERAPDERMA CONCLUSION
Clinical protocols provide a framework for structuring treatment but never replace professional judgement or the individual assessment of each patient.
Pyruvic Peel 30% makes it possible to develop personalised programmes aimed at improving skin texture, promoting the balance of excess sebum, optimising the appearance of pores and integrating advanced Skin Quality strategies, adapting each protocol according to the observed clinical progression.
Within the TherapDerma Clinical Ecosystem™, every treatment evolves through continuous reassessment, therapeutic personalisation and the integration of complementary procedures, enabling professional practice that is consistent, reproducible, safe and based on scientific evidence, delivering progressive and long-lasting results.
TherapDerma™ Combinations
Integrated protocols to enhance therapeutic planning
Modern aesthetic medicine is founded on the strategic combination of different procedures, carefully selected and sequenced according to each patient’s clinical needs and therapeutic objectives.
Within this context, Pyruvic Peel 30% may be incorporated as one stage within personalised programmes designed to progressively optimise Skin Quality, improve skin texture, promote the balance of excess sebum and facilitate the integration of other treatments where there is an appropriate clinical indication.
Each combination should correspond to a specific therapeutic objective and be planned sequentially, respecting physiological recovery periods and the clinical progression observed between procedures.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% is a versatile tool that can be flexibly integrated with other professional solutions to develop fully personalised programmes.
________________________________________
PYRUVIC PEEL 30% + PERSONALISED MESOTHERAPY
Epidermal renewal and targeted treatment
Once the skin has completed its physiological recovery, Pyruvic Peel 30% may be integrated with personalised mesotherapy protocols when the clinical assessment determines that this combination is appropriate.
The selected formulation will always depend on the therapeutic objectives, the biological characteristics of the skin and the individual needs of each patient.
Objectives of the combination
✔ promote personalised skin rejuvenation programmes;
✔ progressively optimise Skin Quality;
✔ improve skin texture;
✔ complement strategies aimed at balancing excess sebum;
✔ integrate advanced Skin Quality programmes.
Mesotherapy should only be introduced once clinical progression confirms that the skin is ready to begin the next stage of treatment.
________________________________________
PYRUVIC PEEL 30% + PDRN
Planned renewal and regeneration
When the therapeutic objective includes strategies aimed at supporting the physiological processes of skin regeneration, Pyruvic Peel 30% may form part of a sequential treatment plan that subsequently incorporates professional PDRN-based solutions.
The combination of both procedures should always be established within an individualised protocol and following appropriate clinical reassessment.
Objectives of the combination
✔ support the physiological processes of skin regeneration;
✔ progressively optimise Skin Quality;
✔ complement personalised regenerative programmes;
✔ integrate therapeutic strategies aimed at skin recovery.
Each procedure should only be introduced after confirming favourable clinical progression and complete physiological recovery of the skin before commencing the next stage of the protocol.
________________________________________
PYRUVIC PEEL 30% + SKIN BIOSTIMULATION
Preparing the skin for a regenerative strategy
Biostimulation procedures may be incorporated into personalised programmes designed to progressively optimise Skin Quality and support a comprehensive skin rejuvenation strategy.
Where there is an appropriate clinical indication, Pyruvic Peel 30% may be used as a preparatory stage within a sequential therapeutic plan, facilitating the structured integration of complementary procedures.
Objectives of the combination
✔ support structured therapeutic planning;
✔ integrate complementary procedures sequentially;
✔ develop personalised protocols according to the patient’s needs;
✔ enhance physiological skin rejuvenation programmes.
Biostimulation techniques should only be introduced once skin recovery is complete and clinical reassessment confirms that the skin is ready for the next stage of treatment.
________________________________________
PYRUVIC PEEL 30% + RADIOFREQUENCY
Epidermal renewal and complementary technology
Radiofrequency may be incorporated, where there is an appropriate clinical indication, into programmes designed to progressively optimise Skin Quality, improve skin texture and complement skin rejuvenation protocols.
Following appropriate physiological recovery, Pyruvic Peel 30% may form part of a sequential therapeutic strategy combining both procedures in a planned manner.
Objectives of the combination
✔ enhance Skin Quality programmes;
✔ support structured therapeutic planning;
✔ integrate complementary medical-aesthetic technologies;
✔ adapt treatment to the individual needs of the patient.
The sequence of both procedures should always be established while respecting physiological recovery periods and the clinical progression observed between treatment sessions.
________________________________________
PYRUVIC PEEL 30% + LED THERAPY
Renewal and support for the recovery process
LED therapy may be incorporated as a complementary procedure within personalised protocols designed to support the physiological recovery of the skin and optimise treatment continuity.
Its integration should always correspond to a specific clinical indication and form part of a previously planned therapeutic strategy.
Objectives of the combination
✔ support the physiological recovery of the skin;
✔ complement epidermal renewal protocols;
✔ optimise clinical progression between treatment sessions;
✔ integrate into comprehensive treatment programmes.
The selection of the LED protocol should be individualised according to the patient’s clinical characteristics and the established therapeutic objectives.
________________________________________
PYRUVIC PEEL 30% + PROFESSIONAL HOME CARE COSMETICS
Treatment continuity also takes place at home
The results of a professional treatment programme do not depend exclusively on procedures performed in the clinic.
The home skincare routine is an essential part of therapeutic continuity, supporting the skin’s physiological progression between treatment sessions and contributing to the maintenance of the results achieved.
The home care programme may include:
✔ appropriate cleansing products;
✔ personalised professional skincare;
✔ moisturising products;
✔ antioxidants where clinically indicated;
✔ active ingredients selected according to the therapeutic objectives;
✔ daily broad-spectrum photoprotection.
The selection of each product should be individualised according to the biological characteristics of the skin, clinical progression and each patient’s specific needs.
Appropriate adherence to the home care programme is a fundamental element in maintaining therapeutic continuity and supporting the progressive improvement of Skin Quality.
________________________________________
THERAPDERMA CLINICAL ECOSYSTEM™
A therapeutic approach based on integration
At TherapDerma, we understand that the best clinical outcomes do not depend on a single procedure, but on the appropriate planning and integration of every stage of treatment.
Each intervention forms part of a comprehensive therapeutic strategy in which diagnosis, clinical procedures, recovery, follow-up and home care work together in a coordinated manner to meet each patient’s individual needs.
Example of integrated treatment planning
Clinical diagnosis
↓
Definition of therapeutic objectives
↓
Pyruvic Peel 30%
↓
Recovery and clinical reassessment
↓
Mesotherapy · PDRN · Biostimulation (where clinically indicated)
↓
Complementary medical-aesthetic technology
↓
Professional home care cosmetics
↓
Clinical follow-up
↓
Personalised maintenance programme
Each stage should be individualised according to clinical progression, skin response and the established therapeutic objectives.
________________________________________
BENEFITS OF INTEGRATED PROTOCOLS
Integrating Pyruvic Peel 30% into personalised therapeutic programmes makes it possible to develop clinical strategies that are more organised, progressive and adapted to each patient’s specific needs.
The principal benefits include:
✔ facilitating therapeutic planning;
✔ integrating different procedures within a coherent clinical strategy;
✔ progressively optimising Skin Quality;
✔ preparing the skin for subsequent stages of treatment;
✔ appropriately organising the sequence between procedures;
✔ adapting each stage according to the observed clinical progression;
✔ promoting continuity of care;
✔ improving coordination between clinic-based treatments and home care.
The combination of procedures should always correspond to specific therapeutic objectives and form part of a fully individualised treatment plan.
________________________________________
CLINICAL SUMMARY
Clinical Objective Recommended Combination
Balance of excess sebum Pyruvic Peel 30% + Personalised Mesotherapy
Skin regeneration Pyruvic Peel 30% + PDRN
Biostimulation programmes Pyruvic Peel 30% + Skin Biostimulation
Integration with technology Pyruvic Peel 30% + Radiofrequency
Recovery and therapeutic support Pyruvic Peel 30% + LED Therapy
Continuity between treatment sessions Pyruvic Peel 30% + Professional Home Care Cosmetics
All combinations should be planned sequentially, respecting physiological recovery periods and adapting to each patient’s clinical progression.
________________________________________
THERAPDERMA PHILOSOPHY
A clinical strategy, not simply a combination of procedures
At TherapDerma, we understand that every treatment forms part of a much broader therapeutic process.
True clinical value does not lie solely in each individual procedure, but in the way every stage of treatment is integrated to respond precisely to each patient’s specific needs.
This philosophy makes it possible to develop therapeutic programmes that are more organised, personalised and consistent with clinical progression, promoting continuity of care, better coordination between procedures and treatment planning based on scientific criteria.
________________________________________
THERAPDERMA CONCLUSION
The intelligent combination of procedures is one of the cornerstones of modern aesthetic medicine. Its success depends on appropriate planning, the correct sequencing of every stage of treatment and the ability to adapt the therapeutic strategy according to each patient’s clinical progression.
Pyruvic Peel 30% represents a versatile tool within the TherapDerma Clinical Ecosystem™, capable of being progressively integrated with other professional solutions where there is an appropriate clinical indication and always according to professional judgement.
Integration with mesotherapy, PDRN, biostimulation, medical-aesthetic technologies and professional home care cosmetics makes it possible to develop programmes designed to optimise Skin Quality, improve skin texture, promote the balance of excess sebum and maintain therapeutic continuity through personalised, consistent and reproducible protocols.
At TherapDerma, we believe that clinical excellence is achieved when scientific knowledge, therapeutic planning, continuous reassessment and individualised treatment work together in a coordinated manner, making it possible to deliver aesthetic medicine that is safer, more effective and aligned with skin physiology and each patient’s genuine needs.
Frequently Asked Questions (FAQ)
Clear answers to support clinical practice
During the planning and performance of a professional chemical peel, questions commonly arise regarding patient selection, treatment planning and the integration of the procedure into personalised protocols.
The following questions bring together some of the most common enquiries raised by professionals during clinical practice and TherapDerma training programmes.
Their purpose is to facilitate clinical decision-making and complement the information provided in this catalogue, without replacing individualised diagnosis or the official technical instructions for the product.
________________________________________
WHAT TYPE OF PEEL IS PYRUVIC PEEL 30%?
Pyruvic Peel 30% is a professional superficial to superficial-medium chemical peel formulated with 30% Pyruvic Acid, an alpha-keto acid (α-keto acid).
It has been developed to promote progressive epidermal renewal, helping to improve skin texture, optimise the appearance of pores, promote the balance of excess sebum and enhance Skin Quality.
Within individualised treatment protocols, it may be incorporated with the objective of progressively improving:
✔ skin texture;
✔ the appearance of pores;
✔ the balance of excess sebum;
✔ the visual uniformity of the skin;
✔ Skin Quality.
________________________________________
IN WHICH PATIENTS MAY IT BE CONSIDERED?
Pyruvic Peel 30% may be considered when the clinical assessment identifies characteristics compatible with epidermal renewal programmes and the progressive improvement of Skin Quality.
It may typically be considered in patients presenting with:
✔ oily or seborrhoeic skin;
✔ excess sebum;
✔ enlarged pores;
✔ irregular skin texture;
✔ appropriately selected acne-prone skin;
✔ early signs of photoageing.
The final indication will always depend on the clinical diagnosis, the functional condition of the skin and the therapeutic objectives established for each patient.
________________________________________
WHAT IS THE DIFFERENCE BETWEEN PYRUVIC ACID AND OTHER ACIDS USED IN PEELS?
Pyruvic Acid belongs to the alpha-keto acid (α-keto acid) family and has physicochemical properties that differ from those of other acids used in professional chemical peels.
The response achieved during a peel does not depend solely on the type of acid used.
It is also influenced by factors such as:
✔ concentration;
✔ pH;
✔ the vehicle;
✔ exposure time;
✔ application technique;
✔ the functional condition of the skin.
For this reason, the selection of the peel should always be based on the clinical diagnosis and the therapeutic objectives established for each patient.
________________________________________
CAN IT BE USED ON SENSITIVE SKIN?
The indication for Pyruvic Peel 30% should always be based on an individual clinical assessment.
Before initiating the procedure, it is advisable to evaluate:
✔ skin sensitivity;
✔ the presence of erythema;
✔ any history of intolerance;
✔ recently performed procedures;
✔ the cosmetic products used at home.
Patient selection and appropriate treatment planning remain the principal factors in ensuring safety.
________________________________________
HOW MANY TREATMENT SESSIONS ARE USUALLY RECOMMENDED?
There is no fixed number of treatment sessions applicable to every patient.
The duration of the programme will depend on several clinical factors, including:
✔ the initial diagnosis;
✔ the therapeutic objectives;
✔ the response observed after each treatment session;
✔ the skin’s recovery capacity;
✔ clinical progression.
Each treatment session should form part of a personalised therapeutic strategy and should be decided following the appropriate professional reassessment.
________________________________________
HOW FREQUENTLY CAN IT BE APPLIED?
The interval between treatment sessions should be individualised according to each patient’s clinical progression.
Before scheduling another application, it is necessary to confirm that the skin has adequately recovered its physiological condition.
Factors that may be considered when determining the most appropriate frequency include:
✔ the observed skin response;
✔ the degree of recovery;
✔ the intensity of the treatment protocol performed;
✔ the treatment area;
✔ integration with other procedures.
A new treatment session is not recommended while signs of irritation or incomplete recovery persist.
________________________________________
CAN IT BE COMBINED WITH OTHER PROCEDURES?
Yes.
Pyruvic Peel 30% may be integrated into personalised therapeutic programmes where there is an appropriate clinical indication.
Depending on the treatment objectives, it may be combined sequentially with procedures such as:
✔ personalised mesotherapy;
✔ professional PDRN solutions;
✔ biostimulation protocols;
✔ radiofrequency;
✔ LED therapy;
✔ professional home care cosmetics;
✔ other compatible medical-aesthetic technologies.
The combination should always be planned while respecting physiological recovery periods.
________________________________________
IS NEUTRALISATION OF THE PEEL MANDATORY?
Yes.
Pyruvic Peel 30% requires neutralisation at the end of the established exposure time, or earlier if the clinical response indicates that this is appropriate.
Neutralisation should be carried out exclusively using the neutralising solution specified by TherapDerma and in accordance with the corresponding technical protocol.
Once the procedure has been completed, it is necessary to verify that the product has been completely removed before commencing post-treatment care.
________________________________________
WHAT POST-TREATMENT CARE SHOULD THE PATIENT FOLLOW?
Post-treatment care forms part of the overall treatment and contributes to appropriate skin recovery between treatment sessions.
Following each procedure, the professional may recommend a home care programme adapted to the patient’s needs, which may include:
✔ gentle cleansing products;
✔ personalised professional skincare;
✔ moisturising products;
✔ daily broad-spectrum photoprotection;
✔ temporary discontinuation of potentially irritating products;
✔ avoiding other procedures until recovery is complete.
Adherence to these recommendations contributes to maintaining treatment continuity.
________________________________________
CAN IT BE USED THROUGHOUT THE YEAR?
The possibility of performing a chemical peel does not depend solely on the time of year, but on the clinical assessment and each patient’s individual circumstances.
Before planning treatment, the following should be evaluated:
✔ skin phototype;
✔ anticipated sun exposure;
✔ the individual’s risk of pigmentary alterations;
✔ the treatment area;
✔ the patient’s ability to maintain appropriate photoprotection.
Where circumstances may compromise skin recovery, it may be advisable to modify the protocol or temporarily postpone the procedure.
________________________________________
CAN IT FORM PART OF SKIN REJUVENATION PROGRAMMES?
Yes.
Where there is an appropriate clinical indication, Pyruvic Peel 30% may be incorporated into personalised programmes designed to progressively optimise Skin Quality.
Within these protocols, it may contribute to promoting:
✔ a more even skin texture;
✔ an improved appearance of pores;
✔ the balance of excess sebum;
✔ enhanced Skin Quality.
Like any professional procedure, it should be integrated into a comprehensive therapeutic strategy that includes photoprotection, home care and other treatments where the clinical diagnosis indicates they are appropriate.
________________________________________
WHAT IS THE PRIMARY OBJECTIVE OF PYRUVIC PEEL 30%?
The primary objective of Pyruvic Peel 30% is to promote progressive epidermal renewal aimed at improving skin texture, optimising the appearance of pores, promoting the balance of excess sebum and enhancing Skin Quality.
Its use may contribute to:
✔ improving skin texture;
✔ optimising the appearance of pores;
✔ promoting the balance of excess sebum;
✔ promoting a more even appearance;
✔ complementing professional Skin Quality programmes.
Treatment planning should always be adapted to each patient’s specific needs.
________________________________________
QUICK SUMMARY
Key concepts about Pyruvic Peel 30%
✔ Professional superficial to superficial-medium chemical peel with 30% Pyruvic Acid.
✔ Professional-use alpha-keto acid (α-keto acid).
✔ Promotes progressive epidermal renewal.
✔ Helps improve skin texture and the appearance of pores.
✔ Promotes the balance of excess sebum and Skin Quality.
✔ Indicated only following an individual clinical assessment.
✔ Can be integrated into personalised TherapDerma Clinical Ecosystem™ protocols.
✔ Compatible with sequential therapeutic strategies where professionally indicated.
✔ Mandatory neutralisation following the official technical protocol.
✔ Treatment planning, follow-up and clinical reassessment form part of the overall treatment.
________________________________________
THERAPDERMA CONCLUSION
The Frequently Asked Questions provide a practical reference tool designed to support daily clinical practice and answer the most common questions relating to the use of Pyruvic Peel 30%.
Beyond the characteristics of the formulation itself, the success of a chemical peel depends on appropriate patient selection, individualised treatment planning, a rigorous application technique and continuous monitoring of clinical progression.
Within the TherapDerma Clinical Ecosystem™, Pyruvic Peel 30% is integrated as a therapeutic tool designed to develop personalised programmes for improving skin texture, optimising Skin Quality and promoting physiological skin rejuvenation, always based on objective clinical criteria.
Our commitment is to provide solutions supported by scientific knowledge, promoting aesthetic medicine that is responsible, personalised and focused on achieving progressive, reproducible results while respecting skin physiology.
Related Content
Discover the TherapDerma professional universe
Modern aesthetic medicine requires a comprehensive approach that combines scientific knowledge, clinical planning and continuous professional development.
For this reason, Pyruvic Peel 30% forms part of the TherapDerma Clinical Ecosystem™, a professional environment that integrates scientific resources, clinical protocols, technologies, training programmes and complementary solutions designed to support professionals throughout every stage of clinical practice.
In addition to this catalogue, TherapDerma provides a collection of guides, protocols and tools that enable the development of personalised, structured treatments based on the available scientific evidence.
________________________________________
THERAPDERMA PEELING COLLECTION™
A collection designed for different clinical objectives
The TherapDerma Peeling Collection brings together a range of professional solutions that allow the selection of the most appropriate acid and concentration according to each patient’s clinical characteristics.
The range includes different formulations designed to address multiple therapeutic needs while maintaining a common philosophy based on personalised treatment.
Available Collection
✔ Glycolic Peel
✔ Lactic Peel
✔ Malic Peel
✔ Mandelic Peel
✔ Salicylic Peel
✔ Pyruvic Peel
✔ TCA Peel
Each formulation has been developed to integrate into professional treatment protocols adapted to different clinical indications.
________________________________________
THERAPDERMA MESOTHERAPY COLLECTION™
Professional solutions for personalised treatment protocols
The TherapDerma Mesotherapy Collection brings together formulations developed to complement aesthetic medicine programmes tailored to each patient’s individual needs.
It includes solutions designed for different treatment areas, including:
✔ skin revitalisation;
✔ professional hydration;
✔ skin rejuvenation programmes;
✔ biostimulation;
✔ skin regeneration;
✔ body treatment protocols;
✔ hair restoration treatments.
Each formulation forms part of a personalised therapeutic approach and may be integrated into clinical strategies designed by the professional.
________________________________________
THERAPDERMA TECHNOLOGIES™
Technology supporting clinical practice
TherapDerma medical-aesthetic technologies have been selected to expand the professional’s therapeutic possibilities and complement different treatment programmes.
The collection includes devices designed for a variety of clinical applications, making it possible to develop treatment protocols adapted to each patient’s objectives.
The combined use of technology and professional procedures facilitates clinical practice that is more versatile, organised and personalised.
________________________________________
THERAPDERMA CLINICAL PROTOCOLS™
Protocols developed to facilitate clinical planning
TherapDerma provides structured treatment protocols that serve as a guide for organising different treatments within professional practice.
These documents offer a clear methodology for therapeutic planning, promoting the standardisation of procedures while maintaining the necessary level of clinical personalisation.
The protocols are intended as support tools and should always be adapted according to professional judgement and each patient’s individual characteristics.
________________________________________
THERAPDERMA SKINCARE™
Professional skincare to support every treatment
The TherapDerma Skincare™ range has been developed to complement in-clinic procedures through home care programmes adapted to different skin needs.
The collection includes professional solutions designed to support treatment progression and promote continuity of care between treatment sessions.
Its principal categories include:
✔ professional cleansing;
✔ hydration;
✔ skin barrier repair;
✔ antioxidants;
✔ control of excess sebum;
✔ care for acne-prone skin;
✔ photoprotection;
✔ maintenance of Skin Quality.
Each home care programme should be individualised according to the characteristics, functional condition of the skin and the therapeutic objectives established for each patient.
________________________________________
THERAPDERMA PROFESSIONAL EDUCATION™
Scientific education for professionals
Continuous professional development is one of the cornerstones of modern aesthetic medicine.
Through TherapDerma Professional Education™, professionals have access to educational programmes designed to expand their clinical knowledge and keep them up to date with the scientific advances within the sector.
Educational activities include:
✔ specialised courses;
✔ clinical masterclasses;
✔ practical workshops;
✔ treatment protocols;
✔ clinical cases;
✔ scientific updates;
✔ training in new technologies and procedures.
Our objective is to provide tools that contribute to professional development and clinical practice based on knowledge and the available scientific evidence.
________________________________________
THERAPDERMA CLINICAL ECOSYSTEM™
An ecosystem designed for clinical practice
All the resources developed by TherapDerma form part of a unified philosophy in which every tool complements the others and contributes to a comprehensive approach to treatment.
TherapDerma Clinical Ecosystem
Clinical assessment
↓
Therapeutic planning
↓
Professional procedure
↓
Complementary treatments
↓
Home care
↓
Clinical follow-up
↓
Maintenance programme
This diagram represents a general model for clinical planning and should always be adapted according to professional judgement and each patient’s specific needs.
________________________________________
RECOMMENDED RESOURCES
To expand your knowledge and explore the different TherapDerma programmes in greater depth, we recommend consulting:
✔ TherapDerma™ Complete Peeling Catalogue
✔ TherapDerma Mesotherapy Collection™
✔ TherapDerma™ Clinical Protocols Manual
✔ TherapDerma Clinical Decision Guide™
✔ TherapDerma Professional Education™
✔ Clinical Combinations Guide
✔ TherapDerma™ Professional Skincare Guide
Each of these resources has been developed to provide practical information and facilitate the planning of personalised treatments within professional aesthetic medicine.
________________________________________
THERAPDERMA CONCLUSION
Scientific knowledge forms the foundation of responsible clinical practice.
For this reason, Pyruvic Peel 30% is not presented as an isolated procedure, but as part of the TherapDerma Clinical Ecosystem™, a professional environment that integrates scientific resources, continuing education, clinical protocols, technologies and complementary solutions to support the professional’s daily clinical practice.
Through the TherapDerma Clinical Ecosystem™, we provide a collection of tools designed to facilitate therapeutic planning, promote scientific advancement and contribute to the development of personalised, consistent and evidence-based aesthetic medicine.
Within this approach, Pyruvic Peel 30% may be integrated into programmes designed to promote epidermal renewal, progressively improve skin texture, optimise the appearance of pores, contribute to the balance of excess sebum and enhance Skin Quality.
Our commitment is to support professionals beyond the procedure itself by providing solutions that contribute to the continuous development of clinical knowledge and to responsible, safe medical practice focused on achieving reproducible results while respecting skin physiology.
TherapDerma Professional Academy™
Where knowledge becomes clinical excellence
Aesthetic medicine is constantly evolving. New scientific knowledge, emerging technologies and advances in clinical procedures make continuous professional development essential to deliver clinical practice that is increasingly evidence-based, responsible and adapted to patients’ needs.
With this vision, TherapDerma Professional Academy™ was created—an international educational platform designed to support doctors, nurses, pharmacists, dentists and other professionals involved in aesthetic medicine, always within the legal and professional framework applicable in each country.
More than simply providing information, our mission is to help professionals develop clinical judgement, strengthen their analytical skills and transform scientific knowledge into responsible therapeutic decision-making.
________________________________________
OUR MISSION
Educating professionals, not simply teaching procedures
At TherapDerma, we believe that true professional excellence does not depend solely on understanding a product or mastering a technique.
Above all, it depends on the ability to interpret scientific information, analyse each clinical situation and select the most appropriate strategy for every patient.
For this reason, our Academy has been developed to promote education based on critical thinking, continuous learning and professional development.
Our purpose is to help professionals:
✔ understand the scientific foundations of aesthetic medicine;
✔ develop a broader clinical perspective;
✔ strengthen professional reasoning;
✔ make evidence-based decisions;
✔ integrate knowledge into daily clinical practice;
✔ adapt every strategy to each patient’s individual needs.
________________________________________
OUR EDUCATIONAL MODEL
Learning to think clinically
Education only becomes truly valuable when it enables professionals to interpret clinical reality more effectively and make decisions with greater confidence, responsibility and clinical judgement.
For this reason, the methodology of TherapDerma Professional Academy™ is based on a continuous learning process that promotes long-term professional development.
Our learning philosophy
Learn
↓
Understand
↓
Analyse
↓
Decide
↓
Apply
↓
Evaluate
↓
Continue learning
This model transforms education into a dynamic process of continuous improvement, where every new insight contributes to professional growth and to clinical practice that is more reflective, structured and purposeful.
________________________________________
AREAS OF EDUCATION
Multidisciplinary knowledge for modern aesthetic medicine
The programmes developed by TherapDerma Professional Academy™ cover different areas related to professional clinical practice, providing a comprehensive perspective on aesthetic medicine.
The main areas of education include:
✔ professional chemical peels;
✔ mesotherapy;
✔ biostimulation;
✔ PDRN;
✔ medical-aesthetic technologies;
✔ Skin Quality;
✔ professional skincare;
✔ clinical protocols;
✔ clinical cases;
✔ clinical documentation;
✔ patient communication;
✔ scientific updates.
Within the field of professional chemical peels, training may cover topics such as the classification of different peeling agents, their physicochemical properties, patient selection criteria, therapeutic planning, application technique, neutralisation and clinical follow-up.
Each programme has been designed to complement the professional’s experience while promoting progressive, structured learning adapted to the latest advances within the sector.
________________________________________
TRAINING FORMATS
Education adapted to different professional profiles
Every professional has different needs, objectives and learning styles. For this reason, TherapDerma Professional Academy™ develops programmes in a variety of formats, allowing access to knowledge in a flexible way adapted to every stage of professional development.
Training formats may include:
✔ face-to-face training;
✔ online training;
✔ scientific webinars;
✔ practical workshops;
✔ specialist masterclasses;
✔ professional congresses and meetings;
✔ clinical case analysis;
✔ scientific update programmes.
All programmes share the same objective: to promote continuous, practical education aligned with the ongoing evolution of aesthetic medicine.
________________________________________
WHAT MAKES THERAPDERMA PROFESSIONAL ACADEMY™ DIFFERENT?
More than teaching procedures—we develop clinical judgement
At TherapDerma, we understand that learning a technique represents only one part of professional development.
Our educational philosophy is designed to train professionals capable of interpreting scientific information, analysing every clinical situation and making well-founded clinical decisions.
The way we teach
We do not simply teach products.
We teach professionals to understand their scientific foundations.
We do not simply teach protocols.
We teach professionals to build therapeutic strategies.
We do not simply teach techniques.
We teach professionals to develop clinical judgement.
We do not simply teach treatments.
We teach professionals to individualise every decision.
We do not simply teach innovation.
We teach professionals to interpret scientific evidence and apply it responsibly.
We do not simply teach how to perform a procedure.
We teach professionals how to assess when it is indicated, how to integrate it and when it should be modified or discontinued.
We believe that knowledge only becomes truly valuable when it helps professionals make better decisions for the benefit of every patient.
________________________________________
TRAINING IN PROFESSIONAL CHEMICAL PEELS
From understanding the acid to clinical treatment planning
Training in professional chemical peels requires understanding far more than the concentration of a formulation.
Every procedure depends on multiple variables that should be analysed together, including:
✔ the chemical nature of the agent used;
✔ the concentration and pH of the formulation;
✔ the vehicle;
✔ the intended depth of action;
✔ the anatomical treatment area;
✔ the clinical characteristics of the skin;
✔ exposure time;
✔ application technique;
✔ the observed skin response;
✔ post-treatment care and clinical follow-up.
Within this area of education, Pyruvic Peel 30% may be studied as a professional peel formulated with 30% Pyruvic Acid, belonging to the alpha-keto acid family.
Knowledge of the product should be integrated into a comprehensive clinical perspective that considers patient selection, therapeutic objectives, professional technique and the individual’s clinical progression.
________________________________________
CASE-BASED LEARNING
Understanding clinical practice through real-life situations
The analysis of clinical cases transforms theoretical principles into practical tools applicable to everyday clinical practice.
Through this approach, professionals can learn to:
✔ interpret the data obtained during clinical assessment;
✔ identify the treatment’s priority objectives;
✔ select the most appropriate procedure;
✔ anticipate potential risk factors;
✔ adapt the treatment protocol according to the skin response;
✔ analyse clinical progression between treatment sessions;
✔ integrate different procedures sequentially;
✔ establish a maintenance programme.
Each clinical case represents an opportunity to develop professional reasoning and understand that the same formulation may require different therapeutic strategies according to each patient’s individual characteristics.
________________________________________
CONTINUOUS SCIENTIFIC DEVELOPMENT
Knowledge evolves—and education must evolve with it
Aesthetic medicine is undergoing constant transformation.
The emergence of new research, formulations, technologies and clinical methodologies requires professionals to review their knowledge regularly and adapt their clinical practice according to the available scientific evidence.
TherapDerma Professional Academy™ promotes a culture of continuous professional development aimed at:
✔ reviewing the scientific foundations of every procedure;
✔ critically analysing new scientific evidence;
✔ identifying significant changes in clinical practice;
✔ updating treatment protocols whenever necessary;
✔ strengthening professional safety and quality;
✔ avoiding the automatic adoption of new trends without appropriate scientific evaluation.
Innovation only becomes truly valuable when it can be interpreted, placed into context and incorporated responsibly into clinical practice.
________________________________________
THERAPDERMA PHILOSOPHY
Knowledge as the driving force behind professional excellence
Innovation constantly evolves.
Products change.
Technologies advance.
Trends are transformed.
However, scientific knowledge and clinical reasoning remain the foundation upon which strong professional practice is built.
For this reason, TherapDerma Professional Academy™ promotes a culture of lifelong learning, where every educational programme represents an opportunity to expand knowledge, refine skills and continue professional development.
Our commitment is to support professionals throughout their careers by providing tools that promote clinical practice that is increasingly safe, structured, personalised and evidence-based.
________________________________________
THERAPDERMA CONCLUSION
TherapDerma Professional Academy™ is one of the cornerstones of the TherapDerma Clinical Ecosystem™, integrating scientific education, professional development and continuous learning within a unified philosophy.
We believe that clinical excellence begins long before the first procedure. It begins with a professional who maintains a commitment to lifelong learning, interprets scientific evidence with critical thinking and adapts every decision to each patient’s individual needs.
Within this educational model, understanding Pyruvic Peel 30% goes far beyond learning an application technique. It involves understanding the properties of Pyruvic Acid as an alpha-keto acid, carrying out appropriate patient assessment, establishing realistic therapeutic objectives and adapting the treatment protocol according to the observed clinical progression.
Beyond delivering educational programmes, our mission is to contribute to the growth of a community of professionals committed to ethical, personalised and knowledge-based aesthetic medicine.
Because the best treatment begins long before the first procedure.
It begins with a professional prepared to make the right decision.
TherapDerma Clinical Decision System™
Transforming scientific knowledge into clinical decision-making
Modern aesthetic medicine requires much more than simply understanding the characteristics of a product.
Every patient presents different biological needs, expectations and recovery capacities. For this reason, treatment selection should not be based solely on personal experience or the automatic application of standardised protocols.
The TherapDerma Clinical Decision System™ (TCDS™) has been developed as a structured framework for clinical reasoning designed to help professionals transform the information obtained during assessment into individualised, scientifically grounded clinical decisions.
Its objective is to facilitate:
✔ clinical assessment;
✔ identification of indications and contraindications;
✔ definition of realistic objectives;
✔ procedure selection;
✔ individualised treatment planning;
✔ clinical observation and reassessment;
✔ clinical documentation;
✔ continuity of care.
The system does not replace professional judgement or the official technical instructions for each product.
________________________________________
STEP 1
CLINICAL ASSESSMENT AND DIAGNOSIS
Every treatment protocol begins with a comprehensive patient assessment.
Before selecting a chemical peel, the professional should identify the skin’s needs and the factors that may influence its biological response.
The assessment may include:
✔ reason for consultation;
✔ patient expectations;
✔ medical and dermatological history;
✔ current medication;
✔ known allergies;
✔ previous medical and aesthetic treatments;
✔ skin type and functional characteristics;
✔ sebaceous activity;
✔ presence of comedones or superficial imperfections;
✔ condition of the stratum corneum;
✔ integrity of the skin barrier function;
✔ skin sensitivity and reactivity;
✔ skin phototype;
✔ presence of lesions, irritation or inflammation;
✔ home skincare routine;
✔ lifestyle and sun exposure;
✔ ability to comply with post-treatment care.
A thorough assessment makes it possible to recognise indications, identify potential contraindications and establish a treatment plan adapted to each patient’s characteristics and needs.
________________________________________
STEP 2
IDENTIFICATION OF THE CLINICAL OBJECTIVE
Following the initial assessment, the primary objective of the treatment protocol should be clearly defined.
For patients who are suitable candidates for Pyruvic Peel 30%, the objectives may include:
✔ promoting progressive epidermal renewal;
✔ contributing to the balance of excess sebum;
✔ progressively improving skin texture;
✔ optimising the appearance of enlarged pores;
✔ promoting a more even skin surface;
✔ complementing programmes for acne-prone skin;
✔ contributing to the improvement of the early signs of photoageing;
✔ progressively optimising Skin Quality;
✔ sequentially preparing the skin for other procedures, where indicated;
✔ maintaining Skin Quality within individualised programmes.
Defining the objective makes it possible to select the most appropriate procedure and communicate realistic expectations to the patient.
________________________________________
STEP 3
PEEL SELECTION
The professional should determine whether Pyruvic Peel 30% represents an appropriate option for the assessed patient.
The decision should take into consideration:
✔ sebaceous activity;
✔ the presence of oily or seborrhoeic skin;
✔ acne-prone skin;
✔ the presence of comedones or superficial imperfections;
✔ the appearance of pores;
✔ skin sensitivity and reactivity;
✔ integrity of the skin barrier function;
✔ the thickness and functional condition of the stratum corneum;
✔ the presence of irregular skin texture;
✔ superficial post-acne marks;
✔ early signs of photoageing;
✔ previous experience with chemical peels;
✔ response to previous treatments;
✔ recovery capacity;
✔ the established therapeutic objectives;
✔ the ability to comply with post-treatment care.
Pyruvic Peel 30% may be considered when the objective is to promote controlled epidermal renewal, improve skin texture, contribute to the balance of excess sebum and optimise Skin Quality in appropriately selected patients.
The final indication should always be established through an individualised clinical assessment.
________________________________________
STEP 4
PROTOCOL PERSONALISATION
The concentration of the peel represents only one of the factors influencing the skin’s response.
The treatment protocol should be adapted by considering:
✔ prior skin preparation;
✔ cleansing and degreasing, where indicated;
✔ quantity of product;
✔ number of layers;
✔ extent of the treatment area;
✔ exposure time;
✔ application technique;
✔ clinical observation during the procedure;
✔ mandatory neutralisation;
✔ complete removal of the product;
✔ post-treatment care;
✔ home skincare;
✔ recovery intervals;
✔ frequency of treatment sessions;
✔ integration with other procedures;
✔ the response observed during previous treatment sessions.
Personalisation makes it possible to adapt the procedure to the functional characteristics of the skin and reduce avoidable risks.
________________________________________
STEP 5
PROFESSIONAL APPLICATION
Application should follow the official technical protocol for TherapDerma Pyruvic Peel 30%.
During the procedure, the professional should monitor:
✔ appropriate preparation of the treatment area;
✔ the quantity and distribution of the product;
✔ the number of layers;
✔ exposure time;
✔ patient comfort;
✔ observed clinical signs;
✔ the need for earlier neutralisation than originally planned;
✔ uniform neutralisation;
✔ complete removal of the product.
Patient safety and the observed skin response should always take precedence over the automatic adherence to a predetermined exposure time.
________________________________________
STEP 6
RECOVERY AND INTEGRATION OF OTHER PROCEDURES
Following the peel, sufficient time should be allowed for skin recovery.
Before incorporating another procedure, the professional should verify:
✔ recovery of the skin barrier function;
✔ absence of persistent irritation;
✔ resolution of significant desquamation;
✔ absence of unexpected reactions;
✔ compliance with home care;
✔ clinical suitability for the next intervention.
Where indicated, the following may subsequently be incorporated:
✔ personalised mesotherapy;
✔ professional PDRN solutions;
✔ biostimulation;
✔ medical-aesthetic technologies;
✔ radiofrequency;
✔ LED therapy;
✔ professional home care cosmetics.
Procedures should not be combined automatically or necessarily within the same treatment session.
The sequence and intervals should respect the characteristics of each procedure and the patient’s biological response.
________________________________________
STEP 7
CLINICAL FOLLOW-UP AND REASSESSMENT
Clinical decision-making continues after every treatment session.
Follow-up makes it possible to assess:
✔ recovery of the skin barrier function;
✔ tolerance;
✔ the appearance of unexpected reactions;
✔ progression of sebaceous activity;
✔ progression of superficial imperfections;
✔ progression of skin texture;
✔ progression of the appearance of pores;
✔ progression of superficial post-acne marks;
✔ progression of the early signs of photoageing;
✔ progression of Skin Quality;
✔ adherence to home care;
✔ patient perception and satisfaction;
✔ the need to continue, modify, postpone or discontinue the treatment protocol.
Each review provides information for adapting the subsequent stages of treatment.
Continuation of the programme should never be considered automatic.
________________________________________
STEP 8
CLINICAL DOCUMENTATION
Every procedure should be appropriately documented.
The record may include:
✔ initial assessment;
✔ indication;
✔ excluded contraindications;
✔ informed consent;
✔ product and concentration used;
✔ batch number and expiry date, where applicable;
✔ treatment area;
✔ skin preparation;
✔ number of layers;
✔ exposure time;
✔ observed response;
✔ timing and method of neutralisation;
✔ recommended post-treatment care;
✔ incidents;
✔ follow-up date;
✔ protocol modifications.
Documentation supports traceability and contributes to continuity of care.
________________________________________
THERAPDERMA™ ALGORITHM
From assessment to clinical decision-making
Clinical assessment
↓
Identification of indications and contraindications
↓
Definition of the clinical objective
↓
Peel selection
↓
Protocol personalisation
↓
Professional application
↓
Mandatory neutralisation
↓
Post-treatment care
↓
Recovery and reassessment
↓
Possible integration of complementary procedures
↓
Follow-up and documentation
↓
Individualised maintenance
This algorithm provides a general framework for the TherapDerma Clinical Decision System™.
It does not represent a universal treatment protocol.
Every stage should be adapted according to the diagnosis, the professional’s legal scope of practice, the official product instructions and the patient’s individual clinical progression.
________________________________________
BENEFITS OF THE THERAPDERMA CLINICAL DECISION SYSTEM™
The use of a structured model can help professionals to:
✔ organise the clinical assessment;
✔ recognise indications and contraindications;
✔ define realistic objectives;
✔ select procedures with greater clinical justification;
✔ individualise every treatment protocol;
✔ improve clinical observation during treatment;
✔ integrate neutralisation and post-treatment care;
✔ promote safer clinical practice;
✔ improve communication with the patient;
✔ facilitate continuity of care;
✔ reduce automatic or insufficiently justified decisions;
✔ document and reassess every stage;
✔ adapt the programme according to the observed clinical response.
Well-organised knowledge supports decisions that are more consistent with each patient’s biological characteristics.
________________________________________
THE TCDS™ PHILOSOPHY
At TherapDerma, we understand that no single product represents the appropriate solution for every patient.
The value of clinical reasoning lies in understanding:
✔ when a treatment may be used;
✔ when it should not be used;
✔ in which patient;
✔ for what objective;
✔ using which technique;
✔ within which treatment sequence;
✔ with which post-treatment care;
✔ and at what point it should be modified or discontinued.
The TherapDerma Clinical Decision System™ does not replace professional judgement, education, responsibility or the applicable legal framework.
It provides a methodology based on:
✔ assessment;
✔ diagnosis;
✔ selection;
✔ personalisation;
✔ clinical observation;
✔ neutralisation;
✔ follow-up;
✔ documentation;
✔ reassessment.
Every decision should be based on the physiology and functional condition of the skin, and not solely on the technical or commercial characteristics of the product.
________________________________________
THERAPDERMA CONCLUSION
The TherapDerma Clinical Decision System™ provides a structured framework to support the assessment, selection and planning of aesthetic medicine treatments.
Rather than offering rigid protocols, it organises clinical reasoning and facilitates the transformation of scientific knowledge into individualised, well-founded clinical decisions.
Integrated within the TherapDerma Clinical Ecosystem™, it enables Pyruvic Peel 30% to be incorporated into a strategy that includes:
✔ diagnosis;
✔ appropriate patient selection;
✔ protocol personalisation;
✔ controlled application;
✔ mandatory neutralisation;
✔ skin recovery;
✔ clinical follow-up;
✔ documentation;
✔ continuity of care.
This approach may contribute to promoting progressive epidermal renewal, together with the gradual improvement of skin texture, the appearance of pores, the balance of excess sebum and Skin Quality, where there is an appropriate professional indication.
Pyruvic Peel 30% contains 30% Pyruvic Acid, an alpha-keto acid whose characteristics should always be evaluated within the full context of the formulation, the functional condition of the skin and the professional application technique employed.
Every decision, every procedure and every stage should be adapted to each patient’s individual needs, tolerance, recovery and biological progression.
+1 (786) 546-8347 (Office)
